8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): January 28, 2015

Acadia Healthcare Company, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	001-35331	46-2492228
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

830 Crescent Centre Drive, Suite 610 Franklin, Tennessee	37067
(Address of Principal Executive Offices)	(Zip Code)

(615) 861-6000

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

As previously disclosed in the Current Reports on Form 8-K and Quarterly Report on Form 10-Q for the three months ended September 30, 2014 for Acadia Healthcare Company, Inc. (the “Company”), each of which were filed with the Securities and Exchange Commission (the “SEC”) on October 30, 2014, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) among the Company, Copper Acquisition Co., Inc., a newly-formed Delaware corporation wholly-owned by the Company (the “Merger Subsidiary”), and CRC Health Group, Inc., a Delaware corporation (“CRC”), pursuant to which, among other things, the Merger Subsidiary will be merged with and into CRC with CRC surviving as a wholly-owned subsidiary of the Company (the “Merger”). Pursuant to the Merger Agreement, among other things, at the effective time of the Merger (i) the Company will issue up to an aggregate of 6.3 million shares of the Company’s common stock, $0.01 par value per share (“Common Stock”), to certain holders of CRC common stock in exchange therefor; (ii) all other CRC securities and equity awards will be cancelled and the holder of such other securities and equity awards will be entitled to receive an amount in cash in exchange therefor based upon the market value of the Common Stock; and (iii) substantially all outstanding indebtedness for borrowed money of CRC will be repaid. The Company expects to close the Merger during the first quarter of 2015 (the “Closing”).

The purpose of this Current Report on Form 8-K is to file the following pro forma and historical financial statements and information which are incorporated by reference herein.

Unaudited Pro Forma Condensed Combined Financial Information of the Company and its Subsidiaries

• Unaudited Pro Forma Condensed Combined Balance Sheet as of September 30, 2014

• Unaudited Pro Forma Condensed Combined Statement of Operations for the fiscal year ended December 31, 2013

• Unaudited Pro Forma Condensed Combined Statement of Operations for the nine months ended September 30, 2014

• Unaudited Pro Forma Condensed Combined Statement of Operations for the nine months ended September 30, 2013

• Notes to Unaudited Pro Forma Condensed Combined Financial Information

CRC Consolidated Financial Statements

Audited Consolidated Financial Statements

• Independent Auditors’ Report

• Audited Consolidated Balance Sheets as of December 31, 2013 and 2012 (As Restated)

• Audited Consolidated Statements of Operations for the years ended December 31, 2013, 2012 (As Restated) and 2011 (As Restated)

• Audited Consolidated Statements of Comprehensive Loss for the years ended December 31, 2013, 2012 (As Restated) and 2011 (As Restated)

• Audited Consolidated Statements of Changes in Equity (Deficit) for the years ended December 31, 2013, 2012 (As Restated) and 2011 (As Restated)

• Audited Consolidated Statements of Cash Flows for the years ended December 31, 2013, 2012 (As Restated) and 2011 (As Restated)

• Notes to Audited Consolidated Financial Statements

Unaudited Condensed Consolidated Financial Statements

• Unaudited Condensed Consolidated Balance Sheets as of September 30, 2014 and December 31, 2013

• Unaudited Condensed Consolidated Statements of Operations for the nine months ended September 30, 2014 and 2013

• Unaudited Condensed Consolidated Statements of Comprehensive Loss for the nine months ended September 30, 2014 and 2013

• Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2014 and 2013

• Notes to Unaudited Condensed Consolidated Financial Statements

Partnerships in Care Investments 1 Limited and its Subsidiaries Unaudited Condensed Combined Financial Statements

• Unaudited Condensed Combined Profit and Loss Account for the six months ended June 30, 2014, 2013 and the twelve months ended December 31, 2013 (Audited)

• Unaudited Condensed Combined Statement of Total Recognised Gains and Losses for the six months ended June 30, 2014, 2013 and the twelve months ended December 31, 2013 (Audited)

• Unaudited Condensed Combined Balance Sheet as of June 30, 2014 and December 31, 2013

• Unaudited Condensed Combined Cash Flow Statement for the six months ended June 30, 2014, 2013 and the twelve months ended December 31, 2013 (Audited)

• Unaudited Reconciliation of Net Cash Flow to Movement in Net Debt for the six months ended June 30, 2014

• Notes to Unaudited Condensed Combined Financial Statements (including a reconciliation to US GAAP (as hereinafter defined) for the six months ended June 30, 2014, 2013 and the twelve months ended December 31, 2013 (Audited))

The unaudited combined financial statements and information of Partnerships in Care Investments 1 Limited (“PiC”) and its subsidiaries have been prepared in accordance with United Kingdom Accounting Standards (“UK GAAP”). UK GAAP differs in certain respects from generally accepted accounting principles in the United States (“US GAAP”). Except where otherwise noted, neither the Company nor PiC has prepared or reconciled, and neither currently intends to prepare or reconcile, the unaudited combined financial statements and information in accordance with US GAAP.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
23.1	Consent of Deloitte & Touche LLP
99.1	Unaudited Pro Forma Condensed Combined Financial Information
99.2	Audited Consolidated Financial Statements of CRC
99.3	Unaudited Condensed Consolidated Financial Statements of CRC
99.4	Unaudited Condensed Combined Financial Statements of PiC and its subsidiaries

Cautionary Statement Regarding Forward-Looking Statements

This Current Report on Form 8-K and the exhibits hereto contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements that address future events, occurrences or results. In some cases, forward-looking statements can be identified by terminology such as “may,” “might,” “will,” “would,” “should,” “could” or the negative thereof. Generally, the words “anticipate,” “believe,” “continue,” “expect,” “intend,” “estimate,” “project,” “plan” and similar expressions used in connection with any discussion of the Merger Agreement and the Closing identify forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results could differ materially and adversely from these forward-looking statements.

The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. Although the Company believes that such expectations, assumptions, estimates and projections are reasonable, forward-looking statements are only predictions and involve known and unknown risks, uncertainties and other factors, many of which are outside of the Company’s control and could cause the Company’s actual results, performance or achievements to differ materially and adversely from any results, performance or achievements expressed or implied by such forward-looking statements.

Given these risks and uncertainties, undue reliance should not be placed on these forward-looking statements. These forward-looking statements are made only as of the date of this Current Report on Form 8-K. The Company does not undertake, and expressly disclaims, any obligation to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ACADIA HEALTHCARE COMPANY, INC.
Date: January 28, 2015	By:	/s/ Christopher L. Howard
		Christopher L. Howard
		Executive Vice President, Secretary and
		General Counsel

EXHIBIT INDEX

Exhibit Number	Description
23.1	Consent of Deloitte & Touche LLP
99.1	Unaudited Pro Forma Condensed Combined Financial Information
99.2	Audited Consolidated Financial Statements of CRC
99.3	Unaudited Condensed Consolidated Financial Statements of CRC
99.4	Unaudited Condensed Combined Financial Statements of PiC and its subsidiaries

EX-23.1

Exhibit 23.1

CONSENT OF INDEPENDENT AUDITORS

We consent to the incorporation by reference in Registration Statement No. 333-196611 on Form S-3 and Registration Statement Nos. 333-177990 and 333-190232 on Form S-8, and Post-Effective Amendment No. 1 to Registration No. 333-175523 to Form S-4 on Form S-8 of our report dated April 30, 2014 (January 27, 2015 as to the items discussed in the first two paragraphs of Note 2 and the last four paragraphs of Note 17) relating to the consolidated financial statements of CRC Health Group, Inc. as of December 31, 2013 and 2012 and for the years ended December 31, 2013, 2012 and 2011, (which report expresses an unmodified opinion and includes an emphasis-of-matter paragraph relating to restatement of the 2012 and 2011 consolidated financial statements for corrections of errors) appearing in this Current Report on Form 8-K of Acadia Healthcare Company, Inc.

/s/ Deloitte & Touche LLP

San Francisco, California

January 27, 2015

EX-99.1

Exhibit 99.1

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

The tables below set forth the unaudited pro forma condensed combined financial data for Acadia Healthcare Company, Inc. (“Acadia”) giving effect to Acadia’s planned merger with CRC Health Group, Inc. (“CRC”) and the related issuance of common stock and debt financing transactions described herein.

With respect to the issuance of common stock, the unaudited pro forma condensed combined financial data is based on the assumption that Acadia will issue 6,262,046 shares of common stock to stockholders of CRC pursuant to the Agreement and Plan of Merger between Acadia, Copper Acquisition Co., Inc. and CRC dated October 29, 2014.

With respect to Acadia’s planned debt financing, the unaudited pro forma condensed combined financial data is based on the assumption that Acadia will issue $300,000,000 of senior unsecured notes, issue $500,000,000 of term loans and borrow on its existing revolving line of credit at the closing date of the merger and also reflects the sixth amendment to Acadia’s credit facility effective as of December 15, 2014.

The unaudited pro forma condensed combined balance sheet as of September 30, 2014 reflects the effect of Acadia’s planned merger with CRC and the related financing transactions described above as if it occurred on September 30, 2014.

The unaudited pro forma condensed combined statements of operations present income (loss) from continuing operations and give effect to each transaction as if it occurred on January 1, 2013.

The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2013 combines the audited consolidated statement of operations of Acadia, the audited consolidated statement of operations of Partnerships in Care Investments 1 Limited (“Partnerships in Care”), the unaudited consolidated statement of operations for Acadia’s other completed acquisitions, the audited consolidated statement of operations of CRC, and the unaudited consolidated statement of operations for CRC’s completed acquisition of Habit Holdings, Inc. (“Habit”) for the period from January 1, 2013 to December 31, 2013.

The unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2014 combines the unaudited consolidated statement of operations of Acadia for that period, the unaudited consolidated statement of operations of Partnerships in Care for the six months ended June 30, 2014, the unaudited consolidated statement of operations for Acadia’s other completed acquisitions for the period prior to acquisition, the unaudited consolidated statement of operations of CRC for the nine months ended September 30, 2014, and the unaudited consolidated statement of operations of Habit for the period from January 1, 2014 to February 28, 2014 (the date CRC closed its acquisition of Habit).

The unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2013 combines the unaudited consolidated statement of operations of Acadia for that period, the unaudited consolidated statement of operations of Partnerships in Care for the nine months ended September 30, 2013, the unaudited consolidated statement of operations for Acadia’s other completed acquisitions for the period prior to acquisition, the unaudited consolidated statement of operations of CRC for the nine months ended September 30, 2013, and the unaudited consolidated statement of operations of Habit for the nine months ended September 30, 2013.

The unaudited pro forma condensed combined financial data has been prepared using the acquisition method of accounting for business combinations under GAAP. The adjustments necessary to fairly present the unaudited pro forma condensed combined financial data have been made based on available information and in the opinion of management are reasonable. Assumptions underlying the pro forma adjustments are described in the accompanying notes, which should be read in conjunction with this unaudited pro forma condensed combined financial data. The pro forma adjustments related to the planned merger with CRC are preliminary and revisions to the fair value of assets acquired and liabilities assumed may have a significant impact on the pro forma adjustments. A final valuation of assets acquired and liabilities assumed has not been completed and the

completion of fair value determinations may result in changes in the values assigned to property and equipment and other assets (including intangibles) acquired and liabilities assumed.

The unaudited pro forma condensed combined financial data is for illustrative purposes only and does not purport to represent what our financial position or results of operations actually would have been had the events noted above in fact occurred on the assumed dates or to project our financial position or results of operations for any future date or future period.

The unaudited pro forma condensed combined financial data should be read in conjunction with the consolidated financial statements and notes thereto of Acadia, Partnerships in Care and CRC.

UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET

As of September 30, 2014

(In thousands)

	Acadia(1)			CRC(2)			Pro Forma Merger Adjustments			Notes			Pro Forma Combined
ASSETS
Current assets:
Cash and cash equivalents	$	42,179		$	21,112		$	(16,112	)		(5	)	$	47,179
Accounts receivable, net		130,253			49,263									179,516
Deferred tax assets		19,782			—									19,782
Other current assets		37,626			15,902									53,528
Total current assets		229,840			86,277			(16,112	)					300,005
Property and equipment, net		1,026,378			128,851									1,155,229
Goodwill		804,647			559,613			463,037			(4	)		1,827,297
Intangible assets, net		21,621			266,639			(251,639	)		(4	)		36,621
Deferred tax assets—noncurrent		15,933			—			29,795			(4	)		45,728
Other assets		42,049			20,425			23,250			(5	)		67,652
								1,900			(5	)
								(19,972	)		(3	)
Total assets	$	2,140,468		$	1,061,805		$	230,259					$	3,432,532
LIABILITIES AND EQUITY
Current liabilities:
Current portion of long-term debt	$	13,320		$	4,709		$	12,041			(6	)	$	30,070
Accounts payable		43,260			5,841									49,101
Accrued salaries and benefits		56,213			22,777									78,990
Other accrued liabilities		29,747			29,002			(7,412	)					51,337
Total current liabilities		142,540			62,329			4,629						209,498
Long-term debt		1,016,002			874,669			42,139			(6	)		1,932,810
Deferred tax liabilities—noncurrent		64,771			137,835			(202,606	)		(4	)		—
Other liabilities		30,579			25,077									55,656
Total liabilities		1,253,892			1,099,910			(155,838	)					2,197,964
Equity:
Common stock		592			36			(36	)		(3	)		655
								63			(4	)
Additional paid-in capital		843,528			358,965			(358,965	)		(3	)		1,219,188
								375,660			(4	)
Retained earnings (accumulated deficit)		79,313			(396,858	)		396,858			(3	)		51,582
								(27,731	)		(5	)
Accumulated other comprehensive loss		(36,857	)		(248	)		248			(3	)		(36,857	)
Total equity (deficit)		886,576			(38,105	)		386,097						1,234,568
Total liabilities and equity	$	2,140,468		$	1,061,805		$	230,259					$	3,432,532

See accompanying notes to unaudited pro forma financial information.

UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS

For the Year Ended December 31, 2013

(In thousands, except per share amounts)

	Acadia(1)			Completed Acquisitions Pro Forma Adjustment(7)			Partnerships in Care(8a)			Pro Forma Adjustments			Notes			Acadia Pro Forma			CRC(2)			Habit(9)			Pro Forma Merger Adjustments			Notes			Pro Forma Combined
Revenue before provision for doubtful accounts	$	735,109		$	33,397		$	267,031		$						$	1,035,537		$	408,809		$	44,294		$						$	1,488,640
Provision for doubtful accounts		(21,701	)		(1,136	)		(11	)								(22,848	)		—			(886	)		(6,948	)		(16	)		(30,682	)
Revenue		713,408			32,261			267,020									1,012,689			408,809			43,408			(6,948	)					1,457,958
Salaries, wages and benefits		407,962			18,148			151,493									577,603			189,682			25,625									792,910
Professional fees		37,171			1,567			11,294									50,032			46,774			1,312									98,118
Supplies		37,569			1,382			9,755									48,706			19,386			1,628									69,720
Rents and leases		10,049			1,575			1,605									13,229			14,035			3,500									30,764
Other operating expenses		80,572			3,635			24,050									108,257			51,775			4,441									164,473
Depreciation and amortization		17,090			687			21,173			(5,420	)		(11a	)		33,530			19,398			1,930			(5,536	)		(11b	)		49,322
Interest expense, net		37,250			2,067			77,373			(60,432	)		(12a	)		56,258			70,699			575			(20,859	)		(12b	)		106,673
Provision for doubtful accounts		—			—			—									—			6,948			—			(6,948	)		(16	)		—
Debt extinguishment costs		9,350			—			—									9,350			—			—									9,350
Goodwill and asset impairments		—			—			—									—			19,341			—									19,341
Transaction-related expenses		7,150			—			—									7,150			—			—			(1,611	)		(13	)		5,539
Total expenses		644,163			29,061			296,743			(65,852	)					904,115			438,038			39,011			(34,954	)					1,346,210
Income (loss) from continuing operations before income taxes		69,245			3,200			(29,723	)		65,852						108,574			(29,229	)		4,397			28,006						111,748
Provision (benefit) for income taxes		25,975			1,200			(12,844	)		16,069			(14	)		30,400			1,790			1,790			11,202			(14	)		45,182
Income (loss) from continuing operations	$	43,270		$	2,000		$	(16,879	)	$	49,783					$	78,174		$	(31,019	)	$	2,607		$	16,804					$	66,566
Earnings per share—income (loss) from continuing operations:
Basic	$	0.87														$	1.33														$	1.02
Diluted	$	0.86														$	1.32														$	1.02
Weighted average shares:
Basic		50,004									8,882			(15a	)		58,886									6,262			(15b	)		65,148
Diluted		50,411									8,882			(15a	)		59,293									6,262			(15b	)		65,555

See accompanying notes to unaudited pro forma financial information.

UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS

For the Nine Months Ended September 30, 2014

(In thousands, except per share amounts)

	Acadia(1)			Completed Acquisitions Pro Forma Adjustment(7)			Partnerships in Care(8b)			Pro Forma Adjustments			Notes			Acadia Pro Forma			CRC(2)			Habit(9)			Pro Forma Merger Adjustments			Notes			Pro Forma Combined
Revenue before provision for doubtful accounts	$	729,784		$	9,492		$	142,312		$						$	881,588		$	340,255		$	7,401		$						$	1,229,244
Provision for doubtful accounts		(20,084	)		(25	)		3									(20,106	)		—			(148	)		(5,718	)		(16	)		(25,972	)
Revenue		709,700			9,467			142,315									861,482			340,255			7,253			(5,718	)					1,203,272
Salaries, wages and benefits		408,680			5,021			84,641									498,342			157,792			4,021									660,155
Professional fees		36,151			467			6,737									43,355			30,297			225									73,877
Supplies		34,722			266			4,868									39,856			15,221			258									55,335
Rents and leases		8,872			574			909									10,355			12,925			522									23,802
Other operating expenses		79,188			1,043			11,644									91,875			41,474			698									134,047
Depreciation and amortization		21,696			51			11,731			(3,329	)		(11a	)		30,149			15,352			381			(3,889	)		(11b	)		41,993
Interest expense, net		33,505			720			43,084			(34,613	)		(12a	)		42,696			54,455			89			(16,733	)		(12b	)		80,507
Provision for doubtful accounts		—			—			—									—			5,718			—			(5,718	)		(16	)		—
Debt extinguishment costs		—			—			—									—			11,622			—									11,622
Gain on foreign currency derivatives		(15,262	)		—			—									(15,262	)		—			—									(15,262	)
Goodwill and asset impairments		—			—			—									—			1,089			—									1,089
Transaction-related expenses		10,834			—			—									10,834			—			—			(667	)		(13	)		10,167
Total expenses		618,386			8,142			163,614			(37,942	)					752,200			345,945			6,194			(27,007	)					1,077,332
Income (loss) from continuing operations before income taxes		91,314			1,325			(21,299	)		37,942						109,282			(5,690	)		1,059			21,289						125,940
Provision (benefit) for income taxes		30,383			497			30			(312	)		(14	)		30,598			254			304			8,516			(14	)		39,672
Income (loss) from continuing operations	$	60,931		$	828		$	(21,329	)	$	38,254					$	78,684		$	(5,944	)	$	755		$	12,773					$	86,268
Earnings per share—income (loss) from continuing operations:
Basic	$	1.14														$	1.33														$	1.32
Diluted	$	1.13														$	1.33														$	1.31
Weighted average shares:
Basic		53,670									5,433			(15a	)		59,103									6,262			(15b	)		65,365
Diluted		53,922									5,433			(15a	)		59,355									6,262			(15b	)		65,617

See accompanying notes to unaudited pro forma financial information.

UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS

For the Nine Months Ended September 30, 2013

(In thousands, except per share amounts)

	Acadia(1)			Completed Acquisitions Pro Forma Adjustment(7)			Partnerships in Care(8b)			Pro Forma Adjustments			Notes			Acadia Pro Forma			CRC(2)			Habit(9)			Pro Forma Merger Adjustments			Notes			Pro Forma Combined
Revenue before provision for doubtful accounts	$	539,230		$	28,328		$	197,718		$						$	765,276		$	309,449		$	33,221		$						$	1,107,946
Provision for doubtful accounts		(15,821	)		(1,035	)		(32	)								(16,888	)		—			(664	)		(5,674	)		(16	)		(23,226	)
Revenue		523,409			27,293			197,686									748,388			309,449			32,557			(5,674	)					1,084,720
Salaries, wages and benefits		298,904			15,130			112,626									426,660			140,044			19,219									585,923
Professional fees		27,294			1,394			8,735									37,423			35,519			984									73,926
Supplies		28,017			1,215			7,220									36,452			14,458			1,221									52,131
Rents and leases		7,377			1,326			1,186									9,889			10,428			2,625									22,942
Other operating expenses		59,424			3,138			16,389									78,951			35,723			3,331									118,005
Depreciation and amortization		12,248			641			15,575			(3,898	)		(11a	)		24,566			14,363			1,448			(3,967	)		(11b	)		36,410
Interest expense, net		27,672			1,622			57,080			(44,375	)		(12a	)		41,999			52,791			431			(15,411	)		(12b	)		79,810
Provision for doubtful accounts		—			—			—									—			5,674			—			(5,674	)		(16	)		—
Debt extinguishment costs		9,350			—			—									9,350			—			—									9,350
Transaction-related expenses		3,813			—			—									3,813			—			—									3,813
Total expenses		474,099			24,466			218,811			(48,273	)					669,103			309,000			29,259			(25,052	)					982,310
Income (loss) from continuing operations before income taxes		49,310			2,827			(21,125	)		48,273						79,285			449			3,298			19,378						102,410
Provision (benefit) for income taxes		18,439			1,060			(9,471	)		12,171			(14	)		22,199			1,261			1,343			7,751			(14	)		32,554
Income (loss) from continuing operations	$	30,871		$	1,767		$	(11,654	)	$	36,102					$	57,086		$	(812	)	$	1,955		$	11,627					$	69,856
Earnings per share—income (loss) from continuing operations:
Basic	$	0.62														$	0.97														$	1.07
Diluted	$	0.61														$	0.97														$	1.07
Weighted average shares:
Basic		49,987									8,882			(15a	)		58,869									6,262						65,131
Diluted		50,213									8,882			(15a	)		59,095									6,262						65,357

See accompanying notes to unaudited pro forma financial information.

NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

(In thousands, except per share amounts)

(1) The amounts in this column represent, for Acadia, actual results for the periods presented.

(2) The amounts in this column represent, for CRC, actual results for the periods presented.

(3) Reflects elimination of equity accounts and existing deferred financing costs of CRC.

(4) Represents adjustments based on preliminary estimates of fair value and the adjustment to goodwill derived from the difference in the estimated total consideration to be transferred by Acadia and the estimated fair value of assets acquired and liabilities assumed by Acadia. The estimated equity consideration is based on the issuance of 6,262,046 shares of Acadia common stock with a par value of $0.01 at an assumed value of $60.00 per share, which results in estimated additional common stock of $63 and additional paid-in capital of $375,660. Final equity consideration will be determined at the closing of the merger.

Estimated equity consideration	$	375,723
Assumption of net indebtedness		875,677
Estimated total consideration		1,251,400
Accounts receivable		49,263
Other current assets		15,902
Property and equipment		128,851
Intangible assets		15,000
Deferred tax assets—noncurrent		94,566
Other long-term assets		453
Accounts payable		(5,841	)
Accrued salaries and benefits		(22,777	)
Other accrued liabilities		(21,590	)
Other long-term liabilities		(25,077	)
Fair value of assets acquired and liabilities assumed	$	228,750
Estimated goodwill		1,022,650
Less: historical goodwill		(559,613	)
Goodwill adjustment	$	463,037

The acquired assets and liabilities will be recorded at their relative fair values as of the closing date of the merger. Estimated goodwill is based upon a determination of the fair value of assets acquired and liabilities assumed that is preliminary and subject to revision as the value of total consideration is finalized and additional information related to the fair value of property and equipment and other assets (including intangible assets) acquired and liabilities assumed becomes available. The actual determination of the fair value of assets acquired and liabilities assumed may differ from that assumed in these unaudited pro forma condensed combined financial statements and such differences may be material. Qualitative factors comprising goodwill include efficiencies derived through synergies expected by coordination of services provided across the combined network of facilities, achievement of operating efficiencies by benchmarking performance and applying best practices throughout the combined company.

(5) The sources and uses of cash in connection with the December 2014 credit facility amendment and merger with CRC are expected to be as follows:

Sources relating to December 2014 credit facility amendment:
Incremental term A loans	$	235,000
Total sources	$	235,000
Uses:
Existing revolver paydown	$	(164,000	)
Incremental term A loans debt financing costs		(1,900	)
Cash proceeds		(69,100	)
Total uses	$	(235,000	)
Sources relating to merger with CRC:
New unsecured senior notes	$	300,000
New term B loans		500,000
Equity issuance to CRC stockholders(a)		375,723
CRC cash on hand		16,112
Revolver borrowing		62,558
Acadia cash on hand		69,100
Total sources	$	1,323,493
Uses:
Equity issuance to CRC stockholders(a)		(375,723	)
CRC debt repayment		(889,377	)
CRC debt prepayment fees		(9,000	)
CRC accrued interest payoff		(7,412	)
Debt financing costs		(23,250	)
Acquisition costs(b)		(18,731	)
Total uses	$	(1,323,493	)

(a) Assumes the issuance of 6,262,046 shares of Acadia common stock with a par value of $0.01 at an assumed value of $60.00 per share in exchange for all outstanding CRC securities. Non-accredited stockholders of CRC will receive cash in lieu of Acadia common stock.

(b) The effect of estimated acquisition costs are not included in the pro forma condensed combined statement of operations for the year ended December 31, 2013 and nine months ended September 30, 2014 and 2013.

(6) Represents the $7,412 payoff of CRC’s accrued interest and the following adjustments to long-term debt:

	Current Portion			Long-term Portion			Total Debt
Incremental term A loans	$	11,750		$	223,250		$	235,000
Revolving line of credit paydown		—			(164,000	)		(164,000	)
Elimination of debt not assumed		(4,709	)		(874,669	)		(879,378	)
New unsecured senior notes		—			300,000			300,000
New term B loans		5,000			495,000			500,000
Revolving line of credit borrowing		—			62,558			62,558
Adjustments	$	12,041		$	42,139		$	54,180

(7) The amounts in this column represent pro forma adjustments for Acadia’s completed acquisitions of (a) two facilities from United Medical Corporation, (b) Cascade Behavioral Hospital and (c) McCallum Place (none of which were individually material) up to the acquisition dates.

(8) The historical financial statements of Partnerships in Care are prepared in accordance with U.K. GAAP and are adjusted to: (i) reconcile the financial statements to U.S. GAAP and (ii) translate the financial statements to U.S. dollars based on the historical exchange rates below. The Partnerships in Care financial statements have been reclassified to conform to Acadia’s financial statement presentation.

		GBP/USD
Year ended December 31, 2013	Average Spot Rate	$	1.5643
Six months ended June 30, 2014	Average Spot Rate	$	1.6687
Nine months ended September 30, 2013	Average Spot Rate	$	1.5461

(a) The amounts below represent results for the year ended December 31, 2013.

	Partnerships in Care (in £, in U.K. GAAP)			U.S. GAAP Adjustments			Notes			Partnerships in Care (in £, in U.S. GAAP)			Partnerships in Care (in $, in U.S. GAAP)
Revenue before provision for doubtful accounts	£	170,703		£						£	170,703		$	267,031
Provision for doubtful accounts		(7	)								(7	)		(11	)
Revenue		170,696									170,696			267,020
Salaries, wages and benefits		98,345			(1,501	)		(10	)		96,844			151,493
Professional fees		7,220									7,220			11,294
Supplies		6,236									6,236			9,755
Rents and leases		1,026									1,026			1,605
Other operating expenses		15,374									15,374			24,050
Depreciation and amortization		11,458			2,077			(10	)		13,535			21,173
Interest expense, net		61,782			(12,320	)		(10	)		49,462			77,373
Transaction-related expenses		—									—			—
Total expenses		201,441			(11,744	)					189,697			296,743
(Loss) income from continuing operations before income taxes		(30,745	)		11,744						(19,001	)		(29,723	)
Benefit for income taxes		(1,715	)		(6,496	)		(10	)		(8,211	)		(12,844	)
Loss from continuing operations	£	(29,030	)	£	18,240					£	(10,790	)	$	(16,879	)

(b) The amounts below represent results for the six months ended June 30, 2014.

	Partnerships in Care (in £, in U.K. GAAP)			U.S. GAAP Adjustments			Notes			Partnerships in Care (in £, in U.S. GAAP)			Partnerships in Care (in $, in U.S. GAAP)
Revenue before provision for doubtful accounts	£	85,283		£						£	85,283		$	142,312
Provision for doubtful accounts		2									2			3
Revenue		85,285									85,285			142,315
Salaries, wages and benefits		51,601			(878	)		(10	)		50,723			84,641
Professional fees		4,037									4,037			6,737
Supplies		2,917									2,917			4,868
Rents and leases		545									545			909
Other operating expenses		6,978									6,978			11,644
Depreciation and amortization		5,991			1,039			(10	)		7,030			11,731
Interest expense, net		31,979			(6,160	)		(10	)		25,819			43,084
Transaction-related expenses		—									—			—
Total expenses		104,048			(5,999	)					98,049			163,614
(Loss) income from continuing operations before income taxes		(18,763	)		5,999						(12,764	)		(21,299	)
(Benefit) provision for income taxes		(1,063	)		1,081			(10	)		18			30
Loss from continuing operations	£	(17,700	)	£	4,918					£	(12,782	)	$	(21,329	)

(c) The amounts below represent results for the nine months ended September 30, 2013.

	Partnerships in Care (in £, in U.K. GAAP)			U.S. GAAP Adjustments			Notes			Partnerships in Care (in £, in U.S. GAAP)			Partnerships in Care (in $, in U.S. GAAP)
Revenue before provision for doubtful accounts	£	127,882		£						£	127,882		$	197,718
Provision for doubtful accounts		(21	)								(21	)		(32	)
Revenue		127,861									127,861			197,686
Salaries, wages and benefits		73,971			(1,126	)		(10	)		72,845			112,626
Professional fees		5,650									5,650			8,735
Supplies		4,670									4,670			7,220
Rents and leases		767									767			1,186
Other operating expenses		10,600									10,600			16,389
Depreciation and amortization		8,515			1,559			(10	)		10,074			15,575
Interest expense, net		46,159			(9,240	)		(10	)		36,919			57,080
Transaction-related expenses		—									—			—
Total expenses		150,332			(8,807	)					141,525			218,811
(Loss) income from continuing operations before income taxes		(22,471	)		8,807						(13,664	)		(21,125	)
Benefit for income taxes		(1,254	)		(4,872	)		(10	)		(6,126	)		(9,471	)
Loss from continuing operations	£	(21,217	)	£	13,679					£	(7,538	)	$	(11,654	)

(9) The amounts in this column represent, for Habit, actual results, up to the acquisition date, for the periods presented.

(10) Reflects adjustments to reconcile U.K. GAAP to U.S. GAAP including (i) a property and equipment impairment charge and related depreciation expense adjustment, which would not have been recorded under U.S. GAAP; (ii) amortization of an interest rate swap, which would not have been recorded under U.S. GAAP; (iii) a share-based payment charge, which would not have been recorded under U.S. GAAP; and (iv) the tax impact of the previous adjustments.

(11) Represents the adjustments to depreciation and amortization expense as a result of recording the property and equipment and intangible assets at preliminary estimates of fair value as of the date of the acquisitions, as follows:

(a) Partnerships in Care

	Amount		Useful Lives (in years)		Monthly Depreciation		Year Ended December 31, 2013			Nine Months Ended September 30, 2014			Nine Months Ended September 30, 2013
Land	$	78,913		N/A	$	—	$	—		$	—		$	—
Building and improvements		478,604		30-50		1,046		11,765			6,275			8,721
Equipment		20,713		3-10		354		3,988			2,127			2,956
		578,230				1,400		15,753			8,402			11,677
Indefinite-lived intangible assets		3,000		N/A		—		—			—			—
Total depreciation and amortization expense								15,753			8,402			11,677
Less: historical depreciation and amortization expense								(21,173	)		(11,731	)		(15,575	)
Depreciation and amortization expense adjustment							$	(5,420	)	$	(3,329	)	$	(3,898	)

(b) CRC and Habit

	Amount		Useful Lives (in years)		Monthly Depreciation		Year Ended December 31, 2013			Nine Months Ended September 30, 2014			Nine Months Ended September 30, 2013
Land	$	20,983		N/A	$	—	$	—		$	—		$	—
Building and improvements		81,526		10-40		878		10,536			7,902			7,902
Equipment		18,828		3-10		438		5,256			3,942			3,942
Construction in progress		7,514		N/A		—		—			—			—
		128,851				1,316		15,792			11,844			11,844
Indefinite-lived intangible assets		15,000		N/A		—		—			—			—
		15,000				—		—			—			—
Total depreciation and amortization expense								15,792			11,844			11,844
Less: historical depreciation and amortization expense of CRC								(19,398	)		(15,352	)		(14,363	)
Less: historical depreciation and amortization expense of Habit								(1,930	)		(381	)		(1,448	)
Depreciation and amortization expense adjustment							$	(5,536	)	$	(3,889	)	$	(3,967	)

(12) Represents an adjustment to interest expense to give effect to the following transactions:

(a) Partnerships in Care

	Year Ended December 31, 2013			Nine Months Ended September 30, 2014			Nine Months Ended September 30, 2013
Interest related to 5.125% Senior Notes due 2022	$	15,375		$	7,688		$	11,531
Interest related to borrowings on revolving credit facility		450			225			337
Interest related to amortization of deferred financing costs		1,116			558			837
Less: historical interest expense of Partnerships in Care		(77,373	)		(43,084	)		(57,080	)
Interest expense adjustment	$	(60,432	)	$	(34,613	)	$	(44,375	)

(b) CRC, assuming an estimated interest rate of 5.1% related to the new debt.

	Year Ended December 31, 2013			Nine Months Ended September 30, 2014			Nine Months Ended September 30, 2013
Interest related to new unsecured senior notes	$	18,000		$	13,500		$	13,500
Interest related to incremental term A loans		8,225			6,169			6,169
Interest related to new term B loans		22,500			16,875			16,875
Interest related to change in the applicable interest rate on term A loans based on Acadia’s consolidated leverage ratio		1,146			859			859
Interest related to revolving line of credit paydown, net of borrowing		(3,049	)		(2,287	)		(2,287	)
Interest related to amortization of deferred financing costs		3,593			2,695			2,695
Less: historical interest expense of CRC		(70,699	)		(54,455	)		(52,791	)
Less: historical interest expense of Habit		(575	)		(89	)		(431	)
Interest expense adjustment	$	(20,859	)	$	(16,733	)	$	(15,411	)

An increase or decrease of 0.125% in the assumed interest rate related to the new unsecured senior notes and new term B loans would result in a change of $1.0 million, $0.8 million and $0.8 million for the year ended December 31, 2013 and nine months ended September 30, 2014 and 2013, respectively.

(13) Reflects the removal of acquisition-related expenses, related to CRC, included in the historical statements of operations.

(14) Reflects adjustments to income taxes to reflect the impact of the above pro forma adjustments applying combined U.S. federal and state statutory tax rates and U.K. statutory rates.

(15) Represents adjustments to weighted average shares used to compute basic and diluted earnings per share for the following.

(a) To reflect the effect of 8,881,794 shares of common stock issued by Acadia, which resulted in an increase in the weighted average shares outstanding of 8,881,794 for the year ended December 31, 2013 and nine months ended September 30, 2014 and 2013 on a pro forma basis. The proceeds of Acadia’s offering of such common stock were used to partially fund Acadia’s acquisition of Partnerships in Care on July 1, 2014.

(b) To reflect the effect of an estimated 6,262,046 shares of common stock to be issued by Acadia.

(16) Reflects reclassification of CRC provision for doubtful accounts to conform to Acadia historical presentation.

EX-99.2

Exhibit 99.2

CRC Health Group, Inc.

Consolidated Financial Statements as of December 31, 2013 and 2012 (Restated), and for the Years

Ended December 31, 2013, 2012 (Restated), and 2011 (Restated), and Independent Auditors’ Report

CRC HEALTH GROUP, INC.

TABLE OF CONTENTS

	Page
INDEPENDENT AUDITORS’ REPORT		1
CONSOLIDATED FINANCIAL STATEMENTS:
Balance Sheets as of December 31, 2013 and 2012 (As Restated)		2
Statements of Operations for the years ended December 31, 2013, 2012 (As Restated) and 2011 (As  Restated)		3
Statements of Comprehensive Loss for the years ended December  31, 2013, 2012 (As Restated) and 2011 (As Restated)		4
Statements of Changes in Equity (Deficit) for the years ended December 31, 2013, 2012 (As  Restated) and 2011 (As Restated)		5
Statements of Cash Flows for the years ended December 31, 2013, 2012 (As Restated) and 2011 (As  Restated)		6
Notes to Consolidated Financial Statements		7 – 40

INDEPENDENT AUDITORS’ REPORT

To the Board of Directors and Stockholders of

CRC Health Group, Inc.:

We have audited the accompanying consolidated financial statements of CRC Health Group, Inc. and subsidiaries (the “Company”), which comprise the consolidated balance sheets as of December 31, 2013 and 2012, and the related consolidated statements of operations, comprehensive loss, changes in equity (deficit), and cash flows for each of the three years in the period ended December 31, 2013, and the related notes to the consolidated financial statements.

Management’s Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company’s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of CRC Health Group, Inc. and subsidiaries as of December 31, 2013 and 2012, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2013, in accordance with accounting principles generally accepted in the United States of America.

Emphasis of Matter

As discussed in Note 2, the accompanying 2012 and 2011 consolidated financial statements have been restated for corrections of errors. Our opinion is not modified with respect to this matter.

/s/ Deloitte & Touche LLP

San Francisco, California

April 30, 2014 (January 27, 2015 as to the items discussed in the first two paragraphs of Note 2 and the last four paragraphs of Note 17)

CRC HEALTH GROUP, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts)

	December 31, 2013			December 31, 2012
				(As Restated, see Note 2)
Assets
Current assets:
Cash and cash equivalents	$	15,559		$	19,058
Accounts receivable, net		37,124			36,737
Prepaid expenses		4,393			4,781
Other current assets		1,980			2,955
Income taxes receivable		4,717			5,280
Deferred income taxes		—			3,715
Current assets of discontinued operations and facilities held-for-sale		4,589			16
Total current assets		68,362			72,542
Property and equipment, net		126,467			130,381
Goodwill		519,103			518,953
Other intangible, assets, net		251,699			294,085
Other assets, net		7,091			21,824
Total assets	$	972,722		$	1,037,785
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	4,739		$	6,801
Accrued payroll and related expenses		18,427			18,333
Accrued interest		9,945			9,412
Accrued expenses		21,299			8,721
Current portion of long-term debt		538			21,350
Deferred revenue		5,183			9,494
Deferred income taxes		202			—
Other current liabilities		827			1,592
Current liabilities of discontinued operations and facilities held-for-sale		8,961			2,372
Total current liabilities		70,121			78,075
Long-term debt		770,749			755,285
Other long-term liabilities		11,597			12,334
Long-term liabilities of discontinued operations and facilities held-for-sale		16,067			6,275
Deferred income taxes		130,311			136,661
Total liabilities		998,845			988,630
Commitments and contingencies
Stockholders’ equity (deficit)
Class A Common stock, $0.001 par value — authorized, 50,000,000 shares; issued and outstanding, 32,678,077, and 32,708,975 at December 31, 2013 and 2012		32			33
Class L Common stock, $0.001 par value — authorized, 5,555,555 shares; issued and outstanding, 3,630,897, and 3,634,330 at December 31, 2013 and 2012		4			4
Additional paid-in capital		358,171			358,422
Accumulated deficit		(384,312	)		(309,233	)
Accumulated other comprehensive loss		(18	)		(71	)
Total stockholders’ equity (deficit)		(26,123	)		49,155
Total liabilities and stockholders’ equity (deficit)	$	972,722		$	1,037,785

See notes to consolidated financial statements

- 2 -

CRC HEALTH GROUP, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands)

	Years Ended December 31,
	2013			2012			2011
				(As Restated, see Note 2)			(As Restated, see Note 2)
Net client service revenues	$	408,809		$	386,063		$	373,539
Operating expenses:
Salaries and benefits		189,682			180,193			169,949
Facilities and other operating costs		131,970			108,730			103,809
Provision for doubtful accounts		6,948			7,184			8,684
Depreciation and amortization		19,398			18,297			18,116
Goodwill and asset impairments		19,341			5,229			639
Total operating expenses		367,339			319,633			301,197
Operating income		41,470			66,430			72,342
Interest expense		(71,662	)		(71,412	)		(65,613	)
Other income		963			1,032			831
Income (loss) from continuing operations before income taxes		(29,229	)		(3,950	)		7,560
Income tax expense		1,790			258			4,384
Income (loss) from continuing operations, net of tax		(31,019	)		(4,208	)		3,176
Loss from discontinued operations, net of tax		(44,060	)		(11,449	)		(28,539	)
Net loss		(75,079	)		(15,657	)		(25,363	)
Net (income) loss attributable to noncontrolling interest		—			434			(934	)
Net loss attributable to CRC Health Group, Inc	$	(75,079	)	$	(15,223	)	$	(26,297	)
Amounts attributable to CRC Health Group, Inc.:
Income (loss) from continuing operations, net of tax	$	(31,019	)	$	(3,774	)	$	2,242
Loss from discontinued operations, net of tax		(44,060	)		(11,449	)		(28,539	)
Net loss attributable to CRC Health Group, Inc	$	(75,079	)	$	(15,223	)	$	(26,297	)

See notes to consolidated financial statements

- 3 -

CRC HEALTH GROUP, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands)

	Years Ended December 31,
	2013			2012			2011
				(As Restated, see Note 2)			(As Restated, see Note 2)
Net loss	$	(75,079	)	$	(15,657	)	$	(25,363	)
Other comprehensive income (loss):
Net change in unrealized gain (loss) on cash flow hedges (net of tax of $42 in 2013, $46 in 2012, $1,391 in 2011)		53			(71	)		2,106
Total comprehensive loss		(75,026	)		(15,728	)		(23,257	)
Comprehensive (income) loss attributable to noncontrolling interest		—			434			(934	)
Comprehensive loss attributable to CRC Health Group, Inc	$	(75,026	)	$	(15,294	)	$	(24,191	)

See notes to consolidated financial statements

- 4 -

CRC HEALTH GROUP, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)

(In thousands, except share amounts)

	Common Stock						Additional Paid-in Capital			Accumulated Deficit			Accumulated Other Comprehensive Loss			Total
	Shares			Amount
Balance — January 1, 2011, as previously reported		36,372,242		$	37		$	351,378		$	(242,856	)	$	(2,106	)	$	106,453
Prior period adjustments, see Note 2		—			—			—			(24,857	)		—			(24,857	)
Balance — January 1, 2011, as restated, see Note 2		36,372,242			37			351,378			(267,713	)		(2,106	)		81,596
Exercise of stock options		126,188			—			111			—			—			111
Repurchase of CRC Health Group, Inc. Class A common stock		(168,356	)		—			(1,212	)		—			—			(1,212	)
Repurchase of CRC Health Group, Inc. Class L common stock		(18,706	)		—			(135	)		—			—			(135	)
Other changes in shares of common stock		2,537			—			—			—			—			—
Issuance of warrants		—			—			4,381			—			—			4,381
Stock-based compensation		—			—			1,389			—			—			1,389
Net loss attributable to CRC Health Group, Inc., as restated, see Note 2		—			—			—			(26,297	)		—			(26,297	)
Unrealized gain on cash flow hedges, net of tax		—			—			—			—			2,106			2,106
Balance — December 31, 2011, as restated, see Note 2		36,313,905			37			355,912			(294,010	)		—			61,939
Exercise of stock options		67,979			—			69			—			—			69
Repurchase of CRC Health Group, Inc. Class A common stock		(5,986	)		—			(255	)		—			—			(255	)
Repurchase of CRC Health Group, Inc. Class L common stock		(727	)		—			(27	)		—			—			(27	)
Other changes in shares of common stock		(31,866	)		—			—			—			—			—
Stock-based compensation		—			—			2,723			—			—			2,723
Net loss attributable to CRC Health Group, Inc., as restated, see Note 2		—			—			—			(15,223	)		—			(15,223	)
Unrealized loss on cash flow hedges, net of tax		—			—			—			—			(71	)		(71	)
Balance — December 31, 2012, as restated, see Note 2		36,343,305			37			358,422			(309,233	)		(71	)		49,155
Repurchase of CRC Health Group, Inc. Class A common stock		(30,898	)		(1	)		(257	)		—			—			(258	)
Repurchase of CRC Health Group, Inc. Class L common stock		(3,433	)		—			(29	)		—			—			(29	)
Stock-based compensation		—			—			35			—			—			35
Net loss		—			—			—			(75,079	)		—			(75,079	)
Unrealized loss on cash flow hedges, net of tax		—			—			—			—			53			53
Balance — December 31, 2013		36,308,974		$	36		$	358,171		$	(384,312	)	$	(18	)	$	(26,123	)

See notes to consolidated financial statements

- 5 -

CRC HEALTH GROUP, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

	Year Ended December 31,
	2013			2012			2011
				(As Restated, see Note 2)			(As Restated, see Note 2)
Cash flows from operating activities
Net loss	$	(75,079	)	$	(15,657	)	$	(25,363	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization		20,427			20,201			20,221
Accretion non-cash interest on PIK loan		22,849			21,241			18,184
Amortization of debt discount and capitalized financing costs		5,715			6,923			5,294
Goodwill and asset impairments		43,978			8,590			9,851
Gain on interest rate swap agreement		—			—			(38	)
Loss from sale of loan program notes receivable		2,537			—			—
Loss on sale of property and equipment		915			828			(63	)
Provision for doubtful accounts		7,158			7,939			9,257
Stock-based compensation		35			2,723			1,389
Deferred income taxes		(2,298	)		3,904			12,306
Changes in assets and liabilities:
Accounts receivable		(8,166	)		(8,272	)		(13,674	)
Prepaid expenses		39			3,587			167
Income taxes receivable and payable		635			(623	)		(1,367	)
Other current assets		930			11			(497	)
Accounts payable		(1,815	)		723			632
Accrued liabilities		17,930			4,886			1,578
Other current liabilities		(3,200	)		(2,361	)		(2,058	)
Other long-term assets		1,976			(985	)		(2,290	)
Other long-term liabilities		9,055			1,366			3,784
Net cash provided by operating activities		43,621			55,024			37,313
Cash flows from investing activities
Additions of property and equipment		(23,114	)		(19,375	)		(17,410	)
Proceeds from sale of loan program		7,084			—			—
Proceeds from sale of property and equipment		450			783			170
Acquisition of businesses, net of cash acquired		(150	)		(141	)		(2,000	)
Other investing activities		—			—			(126	)
Net cash used in investing activities		(15,730	)		(18,733	)		(19,366	)
Cash flows from financing activities
Stock option exercises		—			69			111
Payments made for repurchase of common stock		(287	)		(282	)		(1,347	)
Capitalized financing costs		(390	)		(2,858	)		(3,511	)
Borrowings under revolving line of credit		30,000			18,000			9,500
Repayments under revolving line of credit		(38,000	)		(27,500	)		(7,000	)
Borrowings of long-term debt		—			84,093			—
Repayment of long-term debt		(22,756	)		(98,367	)		(12,628	)
Acquisition of noncontrolling interest		—			(500	)		—
Other financing activities		43			(71	)		—
Net cash used in financing activities		(31,390	)		(27,416	)		(14,875	)
Net increase (decrease) in cash and cash equivalents		(3,499	)		8,875			3,072
Cash and cash equivalents — Beginning of year		19,058			10,183			7,111
Cash and cash equivalents — End of year	$	15,559		$	19,058		$	10,183
Supplemental disclosure of noncash investing and financing activities:
Purchases of property and equipment included in accounts payable	$	1,309		$	1,508		$	411
Payable related to acquisition	$	—		$	11		$	—
Issuance of warrants	$	—		$	—		$	4,381
Supplemental disclosure of cash flow information:
Cash paid for interest	$	41,772		$	42,144		$	42,038
Cash paid for income taxes, net of refunds	$	1,027		$	1,449		$	2,358

See notes to consolidated financial statements

- 6 -

CRC HEALTH GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. BASIS OF PRESENTATION

Basis of Presentation — CRC Health Group, Inc. (“the Company” or “the Group” or “the Parent”) is headquartered in Cupertino, California, and through its wholly owned subsidiaries provides rehabilitation and treatment services related to substance abuse, addiction diseases and other behavioral disorders.

These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The Company’s consolidated financial statements include the accounts of CRC Health Group, Inc. and its consolidated subsidiaries, including CRC Health Corporation. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates — Preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates.

Reclassifications: Discontinued Operations — The Consolidated Statements of Operations have been reclassified for all periods presented to reflect the presentation as discontinued operations of facilities that were (i) closed during 2013 or met the held for sale criteria as discontinued operations as of December 31, 2013 and (ii) closed or sold in 2014 (see Note 17). Unless noted otherwise, discussions in the notes to the consolidated financial statements pertain to continuing operations.

NOTE 2. RESTATEMENT OF CONSOLIDATED FINANCIAL STATEMENTS

Subsequent to the issuance of the Company’s 2013 consolidated financial statements on April 30, 2014, management determined that:

• Income tax expense (benefit) allocated to continuing and discontinued operations for 2012 and 2011 was incorrectly calculated and recorded. The Company recorded certain federal income tax benefits in discontinued operations that should have been recorded in continuing operations. To correct this error in 2012 and 2011, income tax expense related to continuing operations decreased by $ 0.7 million and $1.0 million, respectively, and income tax expense related to discontinued operations increased by $0.7 million and $1.0 million, respectively. There was no impact on net loss attributable to CRC Health Group, Inc.

• Certain services provided in 2013 were recorded net of related expenses, thereby reducing net client service revenue, instead of such services and related expenses being properly recorded on a “gross” basis. To correct this presentation in 2013, net client service revenues and facilities and other operating costs have both been increased by $0.6 million. There was no impact on operating income or net loss attributable to CRC Health Group, Inc.

• Deferred tax assets (related to stock-based compensation) and the associated valuation allowance were both understated due to incorrect calculations. To correct such presentation, deferred tax assets and the associated valuation allowance have both been increased by $1.0 million and $0.5 million, as of December 31, 2013 and 2012 respectively, as presented in the deferred tax table in Note 6. There was no impact on total deferred tax assets.

The above adjustments had no impact on net loss in 2013; however, the Company has restated its 2013, 2012 and 2011 consolidated financial statements to correct these errors. The corrections mentioned above have been reflected in the consolidated financial statements and accompanying notes.

- 7 -

Subsequent to the issuance of the Company’s 2012 consolidated financial statements on April 1, 2013, management determined that:

• Certain deferred tax assets and liabilities and the related income tax expense were incorrectly computed and recorded in the periods from 2006 through December 31, 2012. Income tax expense recorded was overstated by $14.1 million in 2012, understated by $16.0 million in 2011, and understated by $26.7 million in 2010 and prior years.

Specifically, as part of the Company’s 2013 year-end close process, the Company reviewed and supported all historical deferred tax assets and liabilities. The Company also reassessed the timing of the initial recording in 2012 of a valuation allowance against its net operating loss deferred tax assets and its need to record a valuation against other of its deferred tax assets. As a result of this process, the Company identified adjustments in the years 2006 through 2012 as follows:

• Concluded that a full valuation allowance should have been initially recorded against all of the Company’s net deferred tax assets in 2010 rather than federal and state net operating loss carryforwards and credits in 2012. The Company adjusted the valuation allowance accordingly, resulting in additional tax expense of $17.1 million in the years 2010 through 2012.

• Determined that deferred tax assets related to stock-based compensation were not adjusted when the underlying stock options were forfeited or canceled in the years 2006 through 2012. As a result, the Company adjusted its deferred tax assets and recorded tax expense of $5.8 million in the years 2006 through 2012.

• Identified the adjustments below which resulted in additional tax expense of $4.5 million and adjustments to its net operating loss carryforwards in the years 2006 through 2012:

• omitted a permanent difference related to goodwill upon the liquidation of one facility in 2009,

• made a correction to the calculation of deduction for state taxes in the years 2010 through 2012, and

• adjusted various deferred tax assets and liabilities related to goodwill, intangibles, and property and equipment.

• Identified and adjusted reserves related to unrecognized tax benefits and recorded additional tax expense of $1.2 million in the years 2006 through 2012.

• Certain impairments of intangible assets (both those subject to amortization and those not subject to amortization) recorded primarily in discontinued operations in the periods from 2008 through December 31, 2012 were incorrectly computed and recorded due to errors in the allocation of such amounts to specific facilities and other mathematical mistakes. The intangible asset impairment and amortization recorded was understated by $0.2 million in 2012, understated by $1.2 million in 2011 and overstated by $2.6 million in 2010 and prior years.

• The probability of achievement and the requisite service period for certain performance based stock option awards was not properly assessed and revised resulting in an understatement of $0.4 million and an overstatement of $2.0 million in stock compensation expense for 2012 and 2011, respectively.

• Out of period adjustments that were previously identified, recorded and disclosed in the Company’s 2012 consolidated financial statements have been corrected so as to be recorded in the proper year, as follows:

• Management fees reimbursable to the Company’s principal stockholder of $0.7 million that were previously expensed in “facilities and other operating costs” in 2012 have been correctly recorded in 2011;

• Leasehold improvements aggregating $0.4 million previously expensed in “facilities and other operating costs” in 2012 have been correctly recorded in the years 2009 through 2011;

- 8 -

• Adjustments to decrease “facilities, and other operating costs” by $0.9 million and to increase “net loss attributable to noncontrolling interest” that were previously recorded in 2012 have been correctly recorded in 2011;

• Depreciation related to leasehold improvements aggregating $0.5 million previously expensed in “facilities and other operating costs” in 2012 have been correctly recorded in the years 2006 through 2012; and

• Adjustments have been recorded to reflect the income tax effects related to the above corrections.

The net impact of all corrections described above decreased net loss by $14.1 million in 2012, increased net loss by $15.5 million in 2011, and increased net loss by $24.9 million in 2010 and prior years. As a result, the Company has restated its 2012 and 2011 consolidated financial statements to correct these errors. The corrections mentioned above have been reflected in the consolidated financial statements and accompanying disclosures throughout this document.

Corrections to Consolidated Balance Sheet as of December 31, 2012 —

As a result, certain amounts presented in the Company’s consolidated balance sheet as of December 31, 2012 have been restated from the amounts previously reported to correct such errors as shown in the table below.

	As of December 31, 2012
	As Previously Reported			Intangible Assets Amortization Corrections		Stock-based Compensation Expense Corrections			Income Tax Corrections			As Restated
Income taxes receivable	$	1,109		$	—	$	—		$	4,171		$	5,280
Deferred income taxes		6,354			136		—			(2,775	)		3,715
Current assets of discontinued operations		2,628			—		—			(2,612	)		16
Total current assets		73,622			136		—			(1,216	)		72,542
Other intangible assets, net		292,846			1,239		—			—			294,085
Total assets		1,037,626			1,375		—			(1,216	)		1,037,785
Other long-term liabilities		9,379			—		—			2,955			12,334
Deferred income taxes		111,604			—		636			24,421			136,661
Total liabilities		960,618			—		636			27,376			988,630
Additional paid-in capital		360,011			—		(1,589	)		—			358,422
Accumulated deficit		(282,969	)		1,375		953			(28,592	)		(309,233	)
Total equity		77,008			1,375		(636	)		(28,592	)		49,155
Total liabilities and stockholders’ equity		1,037,626			1,375		—			(1,216	)		1,037,785

- 9 -

Reclassifications and Corrections to Consolidated Statements of Operations for the years ended December 31, 2012 and 2011 —

The following tables summarize the effects of the discontinued operations reclassifications (see Note 17) and the corrections on the Company’s consolidated statements of operations for 2012 and 2011 (in thousands):

	For the Year Ended December 31, 2012
	As Previously Reported			Discontinued Operations Reclassifications			Out of Period Corrections			Intangible Assets Amortization Corrections			Stock-based Compensation Expense Corrections			Income Tax Corrections			As Restated and Reclassified
Net client service revenues	$	452,276		$	(66,213	)	$	—		$	—		$	—		$	—		$	386,063
Operating expenses:
Salaries and benefits		215,530			(35,743	)		—			—			406			—			180,193
Facilities and other operating costs		135,422			(26,556	)		(136	)		—			—			—			108,730
Provision for doubtful accounts		7,661			(477	)		—			—			—			—			7,184
Depreciation and amortization		20,254			(1,533	)		(540	)		116			—			—			18,297
Goodwill and asset impairment		8,653			(3,085	)		—			(339	)		—			—			5,229
Total operating expenses		387,520			(67,394	)		(676	)		(223	)		406			—			319,633
Operating income		64,756			1,181			676			223			(406	)		—			66,430
Interest expense		(71,412	)		—			—			—			—			—			(71,412	)
Other income		1,033			(1	)		—			—			—			—			1,032
Loss from continuing operations before income taxes		(5,623	)		1,180			676			223			(406	)		—			(3,950	)
Income tax expense (benefit)		14,966			734			270			89			(162	)		(15,639	)		258
Loss from continuing operations, net of tax		(20,589	)		446			406			134			(244	)		15,639			(4,208	)
Loss from discontinued operations, net of tax		(9,178	)		(446	)		35			(274	)		—			(1,586	)		(11,449	)
Net loss		(29,767	)		—			441			(140	)		(244	)		14,053			(15,657	)
Net income (loss) attributable to noncontrolling interest		(500	)		—			934			—			—			—			434
Net loss attributable to CRC Health Group, Inc	$	(30,267	)	$	—		$	1,375		$	(140	)	$	(244	)	$	14,053		$	(15,223	)

- 10 -

	For the Year Ended December 31, 2011
	As Previously Reported			Discontinued Operations Reclassifications			Out of Period Corrections			Intangible Assets Amortization Corrections			Stock-based Compensation Expense Corrections			Income Tax Corrections			As Restated and Reclassified
Net client service revenues	$	442,564		$	(69,025	)	$	—		$	—		$	—		$	—		$	373,539
Operating expenses:
Salaries and benefits		206,943			(34,999	)		—			—			(1,995	)		—			169,949
Facilities and other operating costs		133,320			(29,338	)		(173	)		—			—			—			103,809
Provision for doubtful accounts		8,962			(278	)		—			—			—			—			8,684
Depreciation and amortization		19,585			(1,596	)		106			21			—			—			18,116
Goodwill and asset impairment		6,104			(5,354	)		—			(111	)		—			—			639
Total operating expenses		374,914			(71,565	)		(67	)		(90	)		(1,995	)		—			301,197
Operating income		67,650			2,540			67			90			1,995			—			72,342
Interest expense		(65,613	)		—			—			—			—			—			(65,613	)
Other income		854			(23	)		—			—			—			—			831
Income from continuing operations before income taxes		2,891			2,517			67			90			1,995			—			7,560
Income tax expense		3,277			1,132			27			36			798			(886	)		4,384
Income (loss) from continuing operations, net of tax		(386	)		1,385			40			54			1,197			886			3,176
Loss from discontinued operations, net of tax		(9,460	)		(1,385	)		—			(770	)		—			(16,924	)		(28,539	)
Net loss		(9,846	)		—			40			(716	)		1,197			(16,038	)		(25,363	)
Net loss attributable to noncontrolling interest		—			—			(934	)		—			—			—			(934	)
Net loss attributable to CRC Health Group, Inc	$	(9,846	)	$	—		$	(894	)	$	(716	)	$	1,197		$	(16,038	)	$	(26,297	)

Corrections to Consolidated Statements of Comprehensive Loss for the years ended December 31, 2012 and 2011 —

The following tables summarize the effects of the corrections on the Company’s consolidated statements of comprehensive loss for 2012 and 2011 (in thousands):

	For the Year Ended December 31, 2012
	As Previously Reported			Out of Period Corrections		Intangible Assets Amortization Corrections			Stock-based Compensation Expense Corrections			Income Tax Corrections		As Restated
Net loss	$	(29,767	)	$	441	$	(140	)	$	(244	)	$	14,053	$	(15,657	)
Other comprehensive loss		(71	)		—		—			—			—		(71	)
Total comprehensive loss		(29,838	)		441		(140	)		(244	)		14,053		(15,728	)
Comprehensive income (loss) attributable to noncontrolling interest		(500	)		934		—			—			—		434
Comprehensive loss attributable to CRC Health Group, Inc	$	(30,338	)	$	1,375	$	(140	)	$	(244	)	$	14,053	$	(15,294	)

- 11 -

	For the Year Ended December 31, 2011
	As Previously Reported			Out of Period Corrections			Intangible Assets Amortization Corrections			Stock-based Compensation Expense Corrections		Income Tax Corrections			As Restated
Net loss	$	(9,846	)	$	40		$	(716	)	$	1,197	$	(16,038	)	$	(25,363	)
Other comprehensive income		2,106			—			—			—		—			2,106
Total comprehensive loss		(7,740	)		40			(716	)		1,197		(16,038	)		(23,257	)
Comprehensive income (loss) attributable to noncontrolling interest		—			(934	)		—			—		—			(934	)
Comprehensive loss attributable to CRC Health Group, Inc	$	(7,740	)	$	(894	)	$	(716	)	$	1,197	$	(16,038	)	$	(24,191	)

Corrections to Consolidated Statements of Changes in Equity (Deficit) for the years ended December 31, 2012 and 2011 —

The following tables summarize the effects of the corrections to the accumulated deficit as of January 1, 2011, and additional paid-in capital for 2012 and 2011 as presented in the Company’s consolidated statements of changes in equity (deficit) for 2012 and 2011 (in thousands). See above for the effects of the corrections on net loss and accumulated deficit for 2012 and 2011.

	Accumulated Deficit
Balance — January 1, 2011, as previously reported	$	(242,856	)
Out of period corrections		(481	)
Intangible assets amortization corrections		1,600
Income tax corrections		(25,976	)
Balance — January 1, 2011, as restated	$	(267,713	)

	Additional Paid-in Capital
	2012		2011
Stock-based compensation, as previously reported	$	2,317	$	3,384
Stock-based compensation expense corrections		406		(1,995	)
Stock-based compensation, as restated	$	2,723	$	1,389

- 12 -

Corrections to Consolidated Statements of Cash Flows for the years ended December 31, 2012 and 2011 —

The following tables summarize the effects of the corrections on the Company’s consolidated statement of cash flows for 2012 and 2011 (in thousands):

	For the Year Ended December 31, 2012
	As Previously Reported			Out of Period Corrections			Intangible Assets Amortization Corrections			Stock-based Compensation Expense Corrections			Income Tax Corrections			As Restated
Cash flows from operating activities
Net loss	$	(29,767	)	$	441		$	(140	)	$	(244	)	$	14,053		$	(15,657	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization		20,445			(540	)		296			—			—			20,201
Accretion non-cash interest on PIK loan		21,241			—			—			—			—			21,241
Amortization of debt discount and capitalized financing costs		6,923			—			—			—			—			6,923
Goodwill and asset impairments		8,653			—			(63	)		—			—			8,590
Loss on sale of property and equipment		1,249			(421	)		—			—			—			828
Provision for doubtful accounts		7,939			—			—			—			—			7,939
Stock-based compensation		2,317			—			—			406			—			2,723
Deferred income taxes		18,433			257			(82	)		(162	)		(14,542	)		3,904
Changes in assets and liabilities:
Accounts receivable		(8,272	)		—			—			—			—			(8,272	)
Prepaid expenses		3,587			—			—			—			—			3,587
Income taxes receivable and payable		(594	)		36			(11	)		—			(54	)		(623	)
Other current assets		11			—			—			—			—			11
Accounts payable		723			—			—			—			—			723
Accrued liabilities		4,659			227			—			—			—			4,886
Other current liabilities		(2,361	)		—			—			—			—			(2,361	)
Other long-term assets		(985	)		—			—			—			—			(985	)
Other long-term liabilities		823			—			—			—			543			1,366
Net cash provided by operating activities		55,024			—			—			—			—			55,024
Cash flows from investing activities
Net cash used in investing activities		(18,733	)		—			—			—			—			(18,733	)
Cash flows from financing activities
Net cash used in financing activities		(27,416	)		—			—			—			—			(27,416	)
Net increase in cash and cash equivalents		8,875			—			—			—			—			8,875

- 13 -

	For the Year Ended December 31, 2011
	As Previously Reported			Out of Period Corrections			Intangible Assets Amortization Corrections			Stock-based Compensation Expense Corrections			Income Tax Corrections			As Restated
Cash flows from operating activities
Net loss	$	(9,846	)	$	40		$	(716	)	$	1,197		$	(16,038	)	$	(25,363	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization		19,762			106			353			—			—			20,221
Accretion non-cash interest on PIK loan		18,184			—			—			—			—			18,184
Amortization of debt discount and capitalized financing costs		5,294			—			—			—			—			5,294
Goodwill and asset impairments		9,010			—			841			—			—			9,851
Gain on interest rate swap agreement		(38	)		—			—			—			—			(38	)
Loss on sale of property and equipment		(117	)		54			—			—			—			(63	)
Provision for doubtful accounts		9,257			—			—			—			—			9,257
Stock-based compensation		3,384			—			—			(1,995	)		—			1,389
Deferred income taxes		(4,768	)		23			(418	)		798			16,671			12,306
Changes in assets and liabilities:
Accounts receivable		(13,674	)		—			—			—			—			(13,674	)
Prepaid expenses		167			—			—			—			—			167
Income taxes receivable and payable		(186	)		5			(60	)		—			(1,126	)		(1,367	)
Other current assets		(497	)		—			—			—			—			(497	)
Accounts payable		632			—			—			—			—			632
Accrued liabilities		1,806			(228	)		—			—			—			1,578
Other current liabilities		(2,058	)		—			—			—			—			(2,058	)
Other long-term assets		(2,290	)		—			—			—			—			(2,290	)
Other long-term liabilities		3,291			—			—			—			493			3,784
Net cash provided by operating activities		37,313			—			—			—			—			37,313
Cash flows from investing activities
Net cash used in investing activities		(19,366	)		—			—			—			—			(19,366	)
Cash flows from financing activities
Net cash used in financing activities		(14,875	)		—			—			—			—			(14,875	)
Net increase in cash and cash equivalents		3,072			—			—			—			—			3,072

NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Cash and Cash Equivalents — Cash includes amounts in demand accounts. At December 31, 2013 and 2012 substantially all cash was on deposit with financial institutions. Cash equivalents are short-term investments with original maturities of three months or less.

Accounts Receivable and Allowance for Doubtful Accounts — The Company’s ability to collect outstanding patient receivables from third party payors is critical to its operating performance and cash flows. The primary collection risk with regard to patient receivables relates to uninsured patient accounts or patient accounts for which primary insurance has paid, but the portion owed by the patient remains outstanding. The Company estimates uncollectible amounts and establishes an allowance for doubtful accounts in order to adjust accounts receivable to estimated net realizable value. In evaluating the collectability of accounts receivable, the Company considers a number of factors, including the age of the accounts, historical collection experience, current economic conditions, and other relevant factors. Accounts

- 14 -

receivable that are determined to be uncollectible based on the Company’s policies are written off to the allowance for doubtful accounts. The following schedule reflects activity associated with the Company’s allowance for doubtful accounts for the years ended December 31, 2013, 2012 and 2011 (in thousands):

	Years ended December 31,
	2013			2012			2011
Balance — beginning of the period	$	4,932		$	6,386		$	4,890
Provision for doubtful accounts		6,948			7,184			8,684
Write-off of uncollectible accounts		(7,019	)		(8,638	)		(7,188	)
Balance — end of the period	$	4,861		$	4,932		$	6,386

Property and Equipment — Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is computed on a straight-line basis over the estimated useful lives of the assets, generally three to seven years, except for buildings, which are depreciated over thirty years. Leasehold improvements are amortized using the straight-line method over the life of the lease, or the estimated useful life of the asset, whichever is shorter. Maintenance and repairs are charged to operations as incurred.

Goodwill and Intangible Assets not Subject to Amortization — The Company tests goodwill for impairment annually, at the beginning of its fourth quarter or more frequently if evidence of possible impairment arises. The Company performs a two-step impairment test on goodwill. In the first step, the Company compares the fair value of the reporting unit being tested, defined as an operating segment or one level below an operating segment, to its carrying value.

The Company determines the fair value of its reporting units using a combination of the income approach and the market approach. Under the income approach, the fair value of a reporting unit is based on the present value of estimated future cash flows. Under the market approach, estimated fair value is based on what investors have paid for similar interests in comparable companies through the development of ratios of market prices to various earnings indications of comparable companies taking into consideration adjustments for growth prospects, debt levels and overall size. If the fair value of the reporting unit exceeds the carrying value of the net assets assigned to that unit, goodwill is not impaired and the Company is not required to perform further testing. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of the reporting unit, then the Company must perform the second step of the impairment test in order to determine the implied fair value of the reporting unit’s goodwill. If the carrying value of a reporting unit’s goodwill exceeds its implied fair value, then the Company records an impairment loss equal to the difference.

The process of evaluating the potential impairment of goodwill is subjective and requires significant estimates and assumptions at many points during the analysis. The Company’s estimated future cash flows are based on assumptions that are consistent with its annual planning process and include estimates for revenue and operating margins and future economic and market conditions. Actual future results may differ significantly from those estimates. In addition, the Company makes certain judgments and assumptions in allocating shared assets and liabilities to determine the carrying values for each of its reporting units tested. Changes in assumptions or circumstances could result in an additional impairment in the period in which the change occurs and in future years. Factors that could cause the Company to record additional goodwill impairment include, but are not limited to:

• Decreases in revenues or increases in operating costs

• Increases in the Company’s borrowing rates or weighted average cost of capital

• Increase in the blended tax rate

• Increases in working capital

• Significant reductions in market multiples utilized in the valuation process

- 15 -

• Significant decreases in market values of comparable companies

• Significant changes in the perpetuity growth rate

The Company’s intangible assets not subject to amortization consist of trademarks and trade names, certificates of need, and regulatory licenses. The Company tests these assets for impairment annually, at the beginning of its fourth quarter or more frequently if evidence of possible impairment arises. The Company applies a fair value-based impairment test to the net book value of the assets using a combination of income and market approaches.

Impairment charges related to goodwill and intangible assets not subject to amortization are included in the consolidated statements of operations under goodwill and asset impairments and loss from discontinued operations, net of tax (see Note 5).

Long-Lived Assets and Intangible Assets Subject to Amortization — The Company tests its long-lived and intangible assets subject to amortization for impairment whenever events or changes in circumstances indicate that the carrying value of those assets may not be recoverable. The assets are tested for impairment at the facility level which represents the lowest level at which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. If the undiscounted future cash flows from the asset tested are less than the carrying value, a loss equal to the difference between the carrying value and the fair market value of the asset is recorded. Fair value is determined using discounted cash flow methods.

The process of evaluating the potential impairment of long-lived assets and intangible assets subject to amortization is subjective and requires significant estimates and assumptions. The Company’s estimated future cash flows are based on assumptions that are consistent with its annual planning process and include estimates for revenue and operating margins and future economic and market conditions. It is possible that the Company’s estimates of undiscounted cash flows may change in the future resulting in the need to reassess the carrying value of its long-lived and intangible assets subject to amortization for impairment.

Impairment charges related to long-lived assets and intangible assets subject to amortization are included in the consolidated statements of operations under goodwill and asset impairments and loss from discontinued operations, net of tax (see Notes 4 and 5).

Capitalized Financing Costs — Costs to obtain long-term debt financing are capitalized and amortized over the expected life of the debt instrument. Net capitalized financing costs are included in the Company’s consolidated balance sheet under other assets. Amortization expenses are included in the Company’s consolidated statement of operations under interest expense. Capitalized financing costs, net as of December 31, 2013 and 2012 were approximately $6.6 million and $9.9 million, respectively.

Revenue Recognition — Revenue is recognized when rehabilitation and treatment services are provided to a client. Client service revenue is reported at the estimated net realizable amounts from clients, third-party payors and others for services rendered. Provisions for estimated third-party payor settlements are provided for in the period the related services are rendered and adjusted in future periods as final settlements are determined. Advance billings for client services are deferred and recognized as the related services are provided. The Company, from time to time, may provide charity care to a limited number of clients. The Company does not record revenues or receivables for charity care provided.

Advertising Costs — Advertising costs, included in facilities and other operating costs, are expensed as incurred. Advertising costs for 2013, 2012 and 2011 were approximately $0.9 million, $1.1 million, and $1.4 million, respectively.

Stock-Based Compensation — The Company measures and recognizes compensation expense for all stock-based payment awards, including employee stock options, based on the award’s grant-date fair value. The Company estimates the fair value of stock options granted using the binomial model in conjunction with Monte

- 16 -

Carlo simulation. For awards that are subject to both a performance and market condition, compensation expense is recognized over the longer of the implicit service period associated with the performance condition or the initial derived service period associated with the market condition (see Note 13).

Income Taxes — The Company is subject to income taxes in the United States and the United Kingdom. Significant judgment is required in determining the provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws.

The Company uses an asset and liability method of accounting for income taxes. Under this method, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carry forwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the balance sheet date.

The Company reviews deferred tax assets for recoverability and establishes a valuation allowance based on historical taxable income, projected future taxable income, applicable tax strategies, and the expected timing of the reversals of existing temporary differences. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company recognizes tax benefits from uncertain tax positions only if management believes that it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. Although the Company believes that uncertain tax positions have been adequately reserved for, we can provide no assurance that the final tax outcome of these matters will not be materially different. The Company makes adjustments to these reserves when facts and circumstances change, such as the closing of a tax audit or the refinement of an estimate. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will affect the provision for income taxes in the period in which such determination is made and could have a material impact on our financial condition and operating results. The provision for income taxes includes the effects of any reserves that we believe are appropriate, as well as the related net interest and penalties.

Restructuring and Discontinued Operations — The Company accounts for facility closures and restructuring costs in accordance with applicable accounting standards and records an obligation for the estimated unrecoverable costs. These costs include one-time employment termination benefits, lease contract termination costs and other associated costs. Additionally, the Company reviews facility closures and facilities held for sale to determine if the cease of use criteria or the held for sale criteria has been met before the end of the accounting period in order to determine appropriate classification in the income statement. Should the Company determine that the cease of use or held for sale criteria have been met prior the end of the accounting period, facility revenues and expenses are reclassified to discontinued operations on the consolidated statements of operations for all periods presented. Assets and liabilities of discontinued operations are classified under assets and liabilities of discontinued operations and facilities held for sale on the Company’s consolidated balance sheets in the period in which the related facilities are classified as discontinued operations or held for sale (see Notes 15 and 16).

Concentration of Credit Risk — Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and accounts receivable. The Company’s cash accounts are maintained with financial institutions in the United States of America and the United Kingdom. At times, deposits in these institutions may exceed federally insured limits. As of December 31, 2013, approximately 39% and 23% of gross accounts receivable and net client service revenue, respectively, and as of December 31, 2012, approximately 38% and 23% of gross accounts receivable and net client service revenue, respectively, were derived from county, state and federal contracts under Medicaid and other programs. In the event of cancellation or curtailment of these programs or default on these accounts receivable, the Company’s operating results and financial position

- 17 -

would be adversely affected. The Company performs ongoing credit evaluations of its third-party insurance payors’ financial condition and generally requires advance payment from its clients who do not have verifiable insurance coverage. The Company maintains an allowance for doubtful accounts to cover potential credit losses based upon the estimated collectability of accounts receivable balances.

Interest Rate Swaps — The fair value of the interest rate swaps were estimated based upon terminal value models. The effective portion of changes in the fair value of interest rate swaps designated and qualifying as cash flow hedges is recorded in accumulated other comprehensive income and is subsequently reclassified into earnings in the period that the hedged forecasted transaction affected earnings. In conjunction with our variable rate indebtedness, we entered into an interest rate swap agreement on December 31, 2012 in the amount of $200.0 million to exchange floating for fixed interest rate payments to reduce interest rate volatility. See Note 8 for additional disclosure on interest rate swaps.

Other Comprehensive Income (Loss) — Other comprehensive income (loss) includes gains and losses that are excluded from net income (loss) and are recorded directly as a component of stockholders’ equity. For the years ended December 31, 2013, 2012 and 2011, the effective portion of changes in fair value of the interest rate swaps designated as cash flow hedges was recorded as other comprehensive income (loss).

Fair Value Measurements — The Company accounts for certain assets and liabilities at fair value. As defined in the authoritative guidance on fair value measurements, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. An asset or liability’s level is based on the lowest level of input that is significant to the fair value measurement. The guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

Level 1:	Quoted prices (unadjusted) in active markets for identical assets or liabilities;
Level 2:	Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;
Level 3:	Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.

Assets and liabilities measured at fair value on a recurring basis — The Company valued its interest rate swaps using terminal values which were derived using proprietary models based upon well-recognized financial principles and reasonable estimates about relevant future market conditions at the valuation date. These instruments were allocated to Level 2 on the fair value hierarchy because the critical inputs into these models, including the relevant yield curves and the known contractual terms of the instrument, were readily available. The fair value of liabilities measured at fair value on a recurring basis as of December 31, 2013 was $0.1 million. See Note 9 for disclosure of fair value measurements and impact of unrealized gain or loss on earnings.

Assets and liabilities measured at fair value on a non-recurring basis —The Company measures, on a non-recurring basis, its long-lived assets and indefinite-lived intangible assets at fair value when performing impairment assessments under the relevant accounting guidance. Nonfinancial liabilities for facility exit activities are also measured at fair value on a non-recurring basis. These instruments were allocated to Level 3 on the fair value hierarchy because the critical inputs into these models are unobservable.

Loan Program —

In December 2013, the Company sold its Loan Program notes receivables portfolio for $7.1 million and ceased to offer a loan program to its students/patients. The Company recognized a $2.5 million loss on the transaction. The

- 18 -

loss is recorded in “facilities and other operating costs” in the Consolidated Statement of Operations for the year ended December 31, 2013. As of December 31, 2012, the Loan Program notes receivables (net of loan loss reserves) were $11.5 million, and included in “other assets, net”. Interest income related to the Loan Program notes was $1.0 million, $1.0 million, and $0.8 million for the years ended December 31, 2013, 2012, and 2011, respectively.

NOTE 4. PROPERTY AND EQUIPMENT

Property and equipment at December 31, 2013 and 2012 consists of the following (in thousands):

	2013			2012
Land (1)	$	21,044		$	21,373
Building and leasehold improvements (1)		112,408			109,111
Furniture and fixtures		15,336			14,162
Computer equipment		15,238			16,033
Computer software		21,975			25,089
Equipment		5,243			7,619
Construction in progress		2,900			11,509
		194,144			204,896
Less accumulated depreciation		(67,677	)		(74,515	)
Property and equipment, net	$	126,467		$	130,381

⁽¹⁾  As of December 31, 2013, Land has been corrected to include $2.0 million that was previously included in Building and leasehold improvements.

Depreciation expense was $14.3 million, $13.5 million, and $12.5 million for the years ended December 31, 2013, 2012 and 2011, respectively.

Asset impairment

In 2013, the Company recognized non-cash impairment charges of $7.5 million related to property and equipment. Additional impairment charges were recognized in discontinued operations during 2013, 2012 and 2011 (see Note 16).

NOTE 5. GOODWILL AND INTANGIBLE ASSETS

Goodwill

Changes to goodwill for the years ended December 31, 2013 and 2012 are as follows (in thousands):

	2013			2012
Balance as of January 1
Goodwill, gross	$	749,875		$	749,875
Accumulated goodwill impairment		(230,922	)		(226,082	)
Total goodwill		518,953			523,793
Activity during the year
Goodwill additions		150			—
Goodwill impairment		—			(4,840	)
Balance as of December 31
Goodwill, gross		750,025			749,875
Accumulated goodwill impairment		(230,922	)		(230,922	)
Total goodwill	$	519,103		$	518,953

- 19 -

As part of the annual valuation process, the Company assessed its goodwill balances during the fourth quarter of 2013 and did not record any impairment. In 2012, the Weight Loss reporting unit recognized a $4.8 million goodwill impairment. The Company did not record any impairment charges to its goodwill during 2011.

Intangible Assets

Total intangible assets at December 31, 2013 and 2012 consist of the following (in thousands):

	December 31, 2013							December 31, 2012
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Intangible assets subject to amortization:
Referral network	$	5,368	$	(1,912	)	$	3,456	$	20,774	$	(6,362	)	$	14,412
Accreditations		—		—			—		8,152		(2,496	)		5,656
Curriculum		794		(283	)		511		4,235		(1,297	)		2,938
Government contracts (including Medicaid)		34,967		(18,455	)		16,512		34,967		(16,124	)		18,843
Managed care contracts		14,400		(11,400	)		3,000		14,400		(9,960	)		4,440
Total intangible assets subject to amortization	$	55,529	$	(32,050	)	$	23,479	$	82,528	$	(36,239	)	$	46,289
Intangible assets not subject to amortization:
Trademarks and trade names							156,302							168,432
Certificates of need							42,784							44,600
Regulatory licenses							29,134							34,764
Total intangible assets not subject to amortization							228,220							247,796
Total intangible assets						$	251,699						$	294,085

The gross carrying amount and accumulated amortization related to impairment charges of intangible assets are excluded from the table above. Amortization expense related to intangible assets subject to amortization was $5.2 million, $5.2 million and $5.5 million, for the years ended December 31, 2013, 2012 and 2011, respectively.

Estimated future amortization expense related to the finite-lived intangible assets at December 31, 2013 is as follows (in thousands):

Year	Amount
2014	$	4,079
2015		4,079
2016		2,759
2017		2,639
2018		2,639
Thereafter		7,284
Total	$	23,479

In 2013, the Company recognized non-cash impairment charges of $10.0 million for trademarks and trade names, $1.8 million related to the certificates of need, and $0.1 million for regulatory licenses. In 2012, the Company recognized a non-cash impairment charge of $0.4 million relative to trademark and trade names. In 2011, the Company recognized a non-cash impairment charge of $0.6 million for trademarks and trade names. Additional impairments of intangible assets are recognized in discontinued operations during 2013, 2012 and 2011 (see Note 16).

- 20 -

NOTE 6. INCOME TAXES

The provision for income taxes attributable to income (loss) from continuing operations consists of the following (in thousands):

	Year Ended December 31,
	2013			2012			2011
Current:
Federal	$	—		$	—		$	—
State		1,854			1,987			2,559
Foreign		(25	)		15			—
Total Current		1,829			2,002			2,559
Deferred:
Federal		305			(887	)		1,096
State		(344	)		(857	)		729
Total Deferred		(39	)		(1,744	)		1,825
Income tax expense from continuing operations	$	1,790		$	258		$	4,384

The reconciliation of income tax computed by applying the U.S. federal statutory rate to the effective tax rate for continuing operations is summarized in the following table:

	Year Ended December 31,
	2013			2012			2011
Statutory federal tax rate		35.0	%		35.0	%		35.0	%
State income taxes (net of federal benefit)		1.8	%		62.7	%		31.7	%
Goodwill impairment		—	%		(47.7	)%		—	%
Nondeductible stock-based compensation		(1.3	)%		(25.7	)%		18.4	%
Provision to tax return adjustments		(0.1	)%		3.9	%		1.0	%
Unrecognized tax benefits (including interest)		(0.7	)%		(27.1	)%		—	%
Change in valuation allowance		(40.2	)%		(11.6	)%		(31.9	)%
Other		(0.6	)%		4.0	%		3.8	%
Effective tax rate from continuing operations		(6.1	)%		(6.5	)%		58.0	%

- 21 -

Deferred tax — Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities used for financial reporting purposes and the amounts used for income tax purposes. The following is a summary of deferred tax assets and liabilities at December 31, 2013 and 2012 (in thousands):

	2013			2012
Deferred tax assets:
Reserves and allowances	$	21,198		$	13,786
Net operating loss carryforwards		31,065			18,990
Research credits		871			871
Stock-based compensation		4,598			5,056
FIN 48 tax benefit		1,755			1,753
Depreciation and amortization		12,484			8,048
Other		105			54
Gross deferred tax assets		72,076			48,558
Valuation allowance		(72,076	)		(43,781	)
Total deferred tax assets	$	—		$	4,777
Deferred tax liabilities:
Intangible assets not subject to amortization	$	(95,032	)	$	(109,551	)
Goodwill		(30,859	)		(23,658	)
State taxes		(32	)		—
Partnerships		(4,590	)		(4,514	)
Total deferred tax liabilities	$	(130,513	)	$	(137,723	)
Net deferred tax liabilities	$	(130,513	)	$	(132,946	)
Current deferred tax assets, net	$	—		$	3,715
Current deferred tax liabilities, net		(202	)		—
Long-term deferred tax liabilities, net	$	(130,311	)	$	(136,661	)

At December 31, 2013, the Company had $79.1 million and $85.0 million of federal and state net operating loss carryforwards, respectively, available to offset future taxable income. If not utilized, these net operating loss carryforwards will expire in varying amounts beginning in 2020 for federal income taxes and 2016 for state income taxes. At December 31, 2013, a portion of the loss may be subject to annual limitation under Internal Revenue Code Section 382.

Future tax benefits are recognized to the extent that realization of such benefits is more likely than not. A valuation allowance is established for those benefits that do not meet the criteria. We have recorded a valuation allowance of $71.1 million and $43.3 million at December 31, 2013 and 2012, respectively. The net increase to the valuation allowance from 2012 to 2013 was $27.8 million related to federal and state net operating loss carryforwards that are not expected to be realized due to the level of forecasted taxable income in these jurisdictions.

The Company files federal and various state income tax returns in the United States and foreign tax jurisdictions in which we have subsidiaries. During the year, the IRS commenced an examination on one of our U.S. federal income tax returns for year 2011 and the State of California commenced an examination of our California income tax returns for the years 2010 and 2011. These examinations have yet concluded and no adjustments have been proposed. The statute of limitations remains open for 2009 through 2013 in the U.S. federal and for 2008 through 2013 in state jurisdictions. Years outside the normal statute of limitation remain open to audit by tax authorities due to tax attributes generated in those earlier years that have been carried forward and may be audited in subsequent years when utilized.

- 22 -

Unrecognized Tax Benefits

The Company recognizes interest and penalties related to unrecognized tax benefits as part of our provision for federal and state income taxes. We accrued $0.7 million and $0.4 million for the payment of interest and penalties, respectively, as of December 31, 2013.

The Company’s total gross unrecognized tax benefits for the years ended December 31, 2013, 2012, and 2011 (in thousands) is as follows:

	Years Ended December 31,
	2013		2012		2011
Balance as of January 1,	$	5,074	$	3,973	$	2,915
Additions		5		1,101		1,058
Balance as of December 31,	$	5,079	$	5,074	$	3,973

NOTE 7. LONG-TERM DEBT

On March 28, 2014, the Company refinanced all of its long-term debt and repaid amounts outstanding as of December 31, 2013 (see Note 17).

Long-term debt at December 31, 2013 and 2012 consists of the following (in thousands):

	December 31, 2013			December 31, 2012
Term loans, net of discount of $1,748 in 2013 and $2,751 in 2012	$	382,056		$	385,875
Revolving line of credit		19,000			27,000
Senior subordinated notes, net of discount of $550 in 2013, and $814 in 2012		176,746			176,482
Payment in kind loan, net of discount of $2,054 in 2013 (including $118,520 of PIK interest), and $3,003 in 2012 (including $95,500 of PIK interest)		193,485			187,260
Other		—			18
Total debt		771,287			776,635
Less: current portion of long-term debt		(538	)		(21,350	)
Total long-term debt	$	770,749		$	755,285

Term Loans and Revolving Line of Credit

Term Loans

On March 7, 2012, the aggregate principal amount of $80.9 million of Term Loans (the “Term Loans B-1”) was refinanced with cash proceeds (net of related fees and expenses) of an aggregate principal amount of $87.6 million of new Term Loans that mature on November 16, 2015 (the “Term Loans B-3”). New creditors and existing Term Loans B-1 creditors represented $67.0 million and $20.6 million of the Term Loans B-3 principal amount, respectively. Of the $20.6 million related to existing creditors, $6.1 million was contributed as additional Term Loan B-3 principal. As a part of the refinancing, the Company repaid $66.4 million of the aggregate principal Term Loans B-1. This repayment was recognized as an extinguishment of debt and $0.2 million of the remaining unamortized issuance costs related to Term Loans B-1 were charged to interest expense during the three months ended March 31, 2012. The Company recognized the refinancing of the remaining aggregate principal amount of $14.5 million with existing Term Loans B-1 creditors as a modification of debt. Refinancing costs of $0.5 million associated with the modified debt were charged to interest expense during the three months ended March 31, 2012. The remaining debt issuance costs of $2.2 million related to the refinancing were capitalized and are being amortized over the life of the Term Loans B-3 using the effective interest rate method. The Term Loans B-3 were issued with an original issue discount of 4.00% which is being amortized over the term of the Term Loans B-3 using the effective interest rate method.

- 23 -

At December 31, 2013, $83.3 million, net of discount of $1.7 million, are outstanding on the Term Loans B-3. Interest on these Term Loans B-3 is payable quarterly at: (i) for LIBOR loans for any interest period, a rate per annum equal to the LIBOR rate as determined by the administrative agent (but not less than 1.50%), plus an applicable margin of 7.00%, subject to an increase to 8.00% during any period that the Company’s public corporate family rating from Moody’s is not at least B3 or the Company’s public corporate credit rating from Standard & Poor’s Ratings Services (“S&P”) is not at least B-, and (ii) for base rate loans, a rate per annum equal to the greater of (x) the prime rate of the administrative agent and (y) the federal funds rate plus one-half of 1.00% (but, in either case, not less than 2.50%), plus an applicable margin of 6.00%, subject to an increase to 7.00% during any period that the Company’s public corporate family rating from Moody’s is not at least B3 or the Company’s public corporate rating credit rating from S&P is not at least B-. At December 31, 2013, the entire amount of these Term Loan B-3 consisted of LIBOR loans and the interest rate thereon was 8.5%.

The Term Loans B-3 are payable in quarterly principal installments of $0.1 million on December 31, 2014 and $0.7 million over the payment period between March 31, 2015 and September 30, 2015, with the remainder due on the maturity date of November 16, 2015.

The Company paid (i) on March 31, 2013, a fee equal to 1.00% of the outstanding principal amount of such lender’s Term Loans B-3 as of such date, and is required to pay (ii) on March 31, 2014, a fee equal to 1.50% of the outstanding principal amount of such lender’s Term Loans B-3 as of such date and (iii) on the Maturity Date, a fee equal to 1.50% of the outstanding principal amount of such lender’s Term Loans B-3 as of such date. These fees are charged to interest expense over the term of the Term Loans B-3 using the effective interest rate method.

The Term Loans B-3 are subject to a 1.00% prepayment premium to the extent they are refinanced, or the terms thereof are amended, in either case, for the purpose of reducing the applicable yield with respect thereto, in each case prior to the first anniversary of the refinancing.

At December 31, 2013, $298.8 million of the remaining Term Loans (the “Term Loans B-2”) are outstanding. The Term Loans B-2 mature on November 16, 2015. Interest on these Term Loans B-2 is payable quarterly at: (i) for LIBOR loans for any interest period, a rate per annum equal to the LIBOR rate as determined by the administrative agent, plus an applicable margin of 4.50% and (ii) for base rate loans, a rate per annum equal to the greater of (x) the prime rate of the administrative agent and (y) the federal funds rate plus one-half of 1.00%, plus an applicable margin of 3.50%. At December 31, 2013, the entire amount of these Term Loans B-2 consisted of LIBOR loans and the interest rate thereon was 4.67%.

The Term Loans B-2 are payable in quarterly principal installments of $0.4 million on December 31, 2014 and $2.4 million over the payment period between March 31, 2015 and September 30, 2015, with the remainder due on the maturity date of November 16, 2015.

The Company is required to apply a certain portion of its excess cash to the principal amount of the Term Loans on an annual basis. Excess cash under the Company’s Credit Agreement is defined as net income attributable to the Company adjusted for certain cash and non-cash items. Required payments, if any are due in March of the subsequent year. There was no excess cash payment required or accrued as of December 31, 2013. The Company made payments related to its excess cash in March 2013 and March 2012 of $4.8 million, and $6.8 million, respectively. The excess cash payment paid in March 2013 has been classified as a current liability as of December 31, 2012.

Revolving Line of Credit

At December 31, 2013, the Company had aggregate revolving credit commitments of $63.0 million which mature on August 16, 2015. Interest is payable quarterly at (i) for LIBOR loans for any interest period, a rate per annum equal to the LIBOR rate as determined by the administrative agent, plus an applicable margin of 4.00%, 3.75%, 3.50% or 3.25%, based upon the Company’s leverage ratio being within certain defined ranges, and

- 24 -

(ii) for base rate loans, a rate per annum equal to the greater of (x) the prime rate of the administrative agent and (y) the federal funds rate plus one-half of 1.00%, plus an applicable margin of 3.00%, 2.75%, 2.50% or 2.25%, based upon the Company’s leverage ratio being within certain defined ranges. Commitment fees are payable quarterly at a rate equal to 0.625% per annum. At December 31, 2013, the amount outstanding under the Company’s Revolving Line of Credit was $19.0 million bearing an average interest rate of 3.99%. At December 31, 2013, the Company’s letters of credit against the revolving commitments were $9.2 million.

The Company’s Term Loans and Revolving Line of Credit are guaranteed by the Company’s Parent and substantially all of the Company’s current and future wholly-owned domestic subsidiaries, and secured by their existing and future property and assets, and secured by a pledge of the Company’s capital stock and the capital stock of the Company’s domestic wholly-owned subsidiaries and up to 65% of the capital stock of first-tier foreign subsidiaries. The Company’s Credit Agreement requires the Company to comply on a quarterly basis with certain financial and other covenants, including a maximum total leverage ratio test and an interest coverage ratio test.

Senior Subordinated Notes — At December 31, 2013, the outstanding aggregate principal amount related to the Company’s 10.75% Senior Subordinated Notes (the “Notes”) due February 1, 2016, was $176.7 million, net of discount of $0.6 million. Interest is payable semiannually. The Company may redeem some or all of the Notes at 100% of their face value, plus accrued and unpaid interest thereon, after February 1, 2014.

If there is a change of control as specified in the indenture, the Company must offer to repurchase the Notes at 101% of their face amount, plus accrued and unpaid interest. The Notes are subordinated to all of the Company’s existing and future senior indebtedness, rank equally with all of the Company’s existing and future senior subordinated indebtedness and rank senior to all of the Company’s existing and future subordinated indebtedness. The Notes are guaranteed on an unsecured senior subordinated basis by each of the Company’s wholly owned subsidiaries that guarantee the Company’s Term Loans and Revolving Line of Credit. The Company’s Notes agreement requires it to comply with certain covenants.

Payment in Kind Loan (“PIK” Loan) — In November 17, 2006, the Company issued a senior unsecured PIK loan of $105.0 million at a 1.00% original issue discount which is not guaranteed by CRC or CRC’s subsidiaries.

On January 20, 2011, the Company amended its senior unsecured PIK loan agreement simultaneously with its Second Amended and Restated Credit Agreement. As a result of this amendment, the maturity of an aggregate amount of $136.6 million of the existing PIK loans was extended from November 17, 2013 to February 1, 2016 (“Extended PIK Loan”). In connection with the Extended PIK Loan, the Company issued warrants to Extending PIK Loan lenders (see Note 12). The Company made payments of $0.6 million and $17.1 million on May 17 and November 17, 2013, respectively, on the remaining existing PIK loans (“Non-Extended PIK Loan”).

At December 31, 2013, aggregate amounts of $195.4 million, will continue to accrue interest and mature on February 1, 2016. Interest is payable at 12.00% until the maturity date. Each lender of the Extending PIK Loan had the option to elect to receive 1.50% of its 12.00% interest in the form of a cash payment (with the remaining 10.50% to be accrued and added to the principal amount).

At December 31, 2013, currently scheduled principal payments of total long-term debt, excluding the effects of the discount on the Term Loans B-3, the Notes and the PIK loan, are as follows (in thousands):

2014	$	538
2015		416,271
2016		358,830
Total	$	775,639

- 25 -

Interest expense — The following table presents the components of interest expense (in thousands):

	Years ended December 31,
	2013			2012			2011
Contractual interest on total debt	$	66,570		$	65,050		$	60,778
Amortization of debt discount and capitalized financing costs		5,715			6,923			5,294
Interest capitalized to property and equipment, net		(623	)		(561	)		(459	)
Total interest expense	$	71,662		$	71,412		$	65,613

NOTE 8. DERIVATIVES AND HEDGING ACTIVITIES

Risk Management Objective of Using Derivatives

The Company is exposed to certain risk arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk primarily by managing the amount, sources, and duration of its debt funding and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s investments and borrowings. However, the Company does not use derivatives for trading or speculative purposes and currently does not have any derivatives that are not designated as hedges.

Cash Flow Hedges of Interest Rate Risk

The Company’s objective in using interest rate derivatives is to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. In 2012 the Company entered into an interest rate swap to hedge the variable cash flows associated with existing variable-rate debt. As of December 31, 2013, the Company had one interest rate derivative designated as a cash flow hedge of interest rate risk, with a $200.0 million notional amount, paying fixed one-month LIBOR at 0.287% and maturing on June 30, 2014. Subsequent to year end, the Company refinanced its debt and this interest rate swap was terminated (see Note 17).

The effective portion of changes in the fair value of a derivative that qualifies and is designated as a cash flow hedge is recorded in accumulated other comprehensive loss and is subsequently reclassified into interest expense as interest payments are made on the Company’s variable-rate debt. The ineffective portion of the change in fair value of this type of derivative is recognized directly in earnings. During the next twelve months, the Company estimates that an additional $0.1 million will be reclassified as an increase to interest expense. As of December 31, 2013, the $0.1 million fair value of this derivative was recorded as “other current liabilities” in the Consolidated Balance Sheet.

- 26 -

The table below presents the effect of the Company’s derivative financial instruments on the Consolidated Statements of Operations (in thousands):

Derivatives Designated as Cash Flow Hedges For the Years Ended December 31,	Amount of Loss Recognized in OCI on Derivative (Effective Portion)									Location of Loss Reclassified From Accumulated OCI into Income (Effective portion)		Amount of Loss Reclassified from Accumulated OCI into Income (Effective Portion)								Location of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion  and Amount Excluded from Effectiveness Testing)		Amount of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion and Amount Excluded from Effectiveness Testing)
	2013			2012			2011					2013			2012		2011					2013			2012		2011
Interest Rate Derivatives
Pay-Fixed Swaps	$	(184	)	$	(117	)	$	(152	)		Interest expense	$	(153	)	$	0	$	(3,649	)		Other Income	$	(43	)	$	0	$	1

Credit-risk-related Contingent Features

The Company has agreements with each of its derivative counterparties that contain a provision where the Company could be declared in default on its derivative obligations if repayment of the underlying indebtedness is accelerated by the lender due to the Company’s default on the indebtedness. As of December 31, 2013, the fair value of derivatives in a net liability position, which includes accrued interest but excludes any adjustment for nonperformance risk, related to these agreements was $0.1 million. If the Company had breached any of these provisions at December 31, 2013, it could have been required to settle its obligations under the agreements at their termination value of $0.1 million.

NOTE 9. FAIR VALUE MEASUREMENTS

Assets and Liabilities Measured at Fair Value on a Recurring Basis

Derivative financial instruments

Currently, the Company uses interest rate swaps to manage its interest rate risk. The valuation of these instruments is determined using widely accepted valuation techniques including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments and the discounted expected variable cash receipts. The variable cash receipts are based on an expectation of future interest rates (forward curves) derived from observable market interest rate forward curves.

The Company incorporates credit valuation adjustments to appropriately reflect both its own nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements. In adjusting the fair value of its derivative contracts for the effect of nonperformance risk, the Company has considered the impact of netting and any applicable credit enhancements, such as collateral postings, thresholds, mutual puts, and guarantees. In conjunction with the FASB’s fair value measurement guidance, the Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.

Although the Company has determined that the majority of the inputs used to value its derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivatives utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. However, as of December 31, 2013, the Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivatives. As a result, the Company has determined that its derivative valuations in their entirety are classified in Level 2 of the fair value hierarchy.

- 27 -

The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2013, aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2013 and 2012 (in thousands):

	Quoted Prices in Active Markets (Level 1)				Significant Other Observable Inputs (Level 2)				Significant Unobservable Inputs (Level 3)				Total Fair Value
	December 31, 2013		December 31, 2012		December 31, 2013		December 31, 2012		December 31, 2013		December 31, 2012		December 31, 2013		December 31, 2012
Assets
Derivative Financial Instruments	$	0	$	0	$	0	$	0	$	0	$	0	$	0	$	0
Liabilities
Derivative Financial Instruments	$	0	$	0	$	106	$	117	$	0	$	0	$	106	$	117

Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

The Company’s goodwill and other intangible assets not subject to amortization are tested and reviewed annually for impairment during the fourth quarter or whenever there is a significant change in events or circumstances that indicate that the fair value of the asset may be less than the carrying amount of the asset. In addition, the Company’s property and equipment and intangibles assets subject to amortization are assessed for recoverability of the carrying value whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.

The following table presents the non-financial assets that were measured and recorded at fair value based on Level 3 inputs on a non-recurring basis during the years ended December 31, 2013 and 2012 (in thousands):

	Year Ended December 31, 2013
	Impairment Charge		Fair Value
Trademarks and trade names	$	9,888	$	39,022
Property and equipment		7,501		2,099
Certificates of need		1,816		17,582
Regulatory licenses		136		—
Total	$	19,341	$	58,703

	Year Ended December 31, 2012
	Impairment Charge		Fair Value
Goodwill	$	4,840	$	2,400
Trademarks and trade names		389		749
Total	$	5,229	$	3,149

Fair Value of Financial Instruments

Financial instruments not measured at fair value on a recurring basis include cash, restricted cash, accounts receivable, net, loan program notes receivable, net, accounts payable, term loans, net, and senior subordinated notes, net. With the exception of financial instruments noted in the following table, the fair value of the Company’s financial instruments approximate carrying value due to their short maturities.

- 28 -

The estimated fair value of financial instruments with long-term maturities is as follows:

	December 31, 2013				December 31, 2012
	Carrying Amount		Fair Value		Carrying Amount		Fair Value (1)
	(in thousands)
Assets
Loan program notes receivable, net	$	—	$	—	$	11,473	$	9,606
Liabilities
Term loans, net	$	382,056	$	406,284	$	385,875	$	402,757
Senior subordinated notes, net		176,746		186,124		176,482		181,248
Payment in kind loan, net		193,485		237,181		187,260		232,666

⁽¹⁾  The fair values as of December 31, 2012 have been corrected from amounts previously reported.

The estimated fair value for loan program notes is primarily based on securitization market conditions for similar loans. The Company’s term loans are measured at fair value based on present value methods using credit spreads derived from market data to discount the projected interest and principal payments. The Company’s senior subordinated notes are measured at fair value based on bond-yield data from market trading activity as well as U.S Treasury rates with similar maturities as the senior subordinated notes to discount the projected interest and principal payments. As of December 31, 2013 and 2012, the estimated fair value of loan program notes, term loans and senior subordinated notes was determined based on Level 3 inputs.

NOTE 10. COMMITMENTS AND CONTINGENCIES

Operating Leases — The Company leases various facilities, offices and equipment under non-cancelable operating leases throughout the United States with various expiration dates through September 2048. Rent expense was $13.3 million, $12.8 million and $12.5 million for the years ended December 31, 2013, 2012, and 2011, respectively. The Company earned $0.6 million, $0.5 million, and $0.5 million in sublease rental income for the years ended December 2013, 2012, and 2011, respectively. The terms of certain facility leases provide for annual scheduled increases in cost adjustments and rental payments on a graduated scale. The Company is party to certain related party leases as a result of the Company’s acquisitions. Such related party leases are due and payable on a monthly basis on similar terms and conditions as the Company’s other leasing arrangements. In addition, the Company is also responsible for certain expenses including property tax, insurance and maintenance costs associated with some of the leases.

Future minimum lease payments under all non-cancelable operating leases at December 31, 2013 are as follows (in thousands):

	Third Party Operating Lease Payments		Related Party Operating Lease Payments		Total Operating Lease Payments
2014	$	12,930	$	286	$	13,216
2015		11,144		272		11,416
2016		8,203		204		8,407
2017		5,820		53		5,873
2018		3,206		—		3,206
Thereafter		25,317		—		25,317
Total minimum lease payments	$	66,620	$	815	$	67,435

Indemnifications — The Company provides for indemnification of directors, officers and other persons in accordance with limited liability agreements, certificates of incorporation, bylaws, articles of association or similar organizational documents, as the case may be. The Company maintains directors’ and officers’ insurance which should enable the Company to recover a portion of any indemnity payments made.

- 29 -

In addition to the above, from time to time the Company provides standard representations and warranties to counterparties in contracts in connection with business dispositions and acquisitions and also provides indemnities that protect the counterparties to these contracts in the event they suffer damages as a result of a breach of such representations and warranties or in certain other circumstances relating to such sales or acquisitions.

While the Company’s future obligations under certain agreements may contain limitations on liability for indemnification, other agreements do not contain such limitations and under such agreements it is not possible to predict the maximum potential amount of future payments due to the conditional nature of the Company’s obligations and the unique facts and circumstances involved in each particular agreement. Historically, no payments have been made under any of these indemnities.

Self-Insurance Plans — The Company has a self-insurance program for workers’ compensation benefits for employees. Self-insurance reserves are based on past claims experience and projected losses for incurred claims and include an estimate of costs for claims incurred but not reported at the balance sheet date. The Company obtains an independent actuarial valuation of the estimated costs of claims reported but not settled, and claims incurred but not reported and may adjust the reserves based on the results of the valuations. Insurance coverage in excess of the per occurrence self-insurance retention has been secured with insurers for specified amounts. The reserve for self-insured workers’ compensation claims was $5.4 million and $5.7 million at December 31, 2013 and 2012, respectively, and is included in accrued liabilities on the consolidated balance sheets.

The Company maintains a self-insurance program for employee group health insurance to consolidate both self-insured and insured plans that had been in existence previously. The self-insured group health plan covers approximately 70% of the Company’s employees enrolled in group health plans. The remaining employees enrolled in group health plans are covered through health maintenance organizations. Insurance coverage, in excess of the per occurrence self-insurance retention, has been secured with insurers for specified amounts. Self-insurance reserves are based on projected costs for incurred claims and include an estimate of costs of claims incurred but not reported at the balance sheet date. The Company obtains an independent actuarial valuation of the estimated costs of claims reported but not settled, and claims incurred but not reported and may adjust the reserves based on the results of the valuations. The reserve for self-insured health insurance claims totaled $2.1 million and $1.9 million at December 31, 2013, and 2012, respectively, and is included in accrued liabilities on the consolidated balance sheets.

Legal Matters — In a complaint initially filed on July 6, 2011, and amended on August 25, 2011, in Multnomah County Circuit Court in Oregon, 17 former students of Mount Bachelor Academy, a previously closed therapeutic boarding school operated by our subsidiary Mount Bachelor Education Center, Inc. (“MBA”) allege claims for intentional and negligent infliction of emotional distress, battery, breach of contract and negligence arising out of their treatment in certain programs of our school. Our subsidiaries, Aspen Education Group, Inc. (“Aspen”) and MBA, are among the defendants in this litigation. The plaintiffs seek a total of $26.0 million in relief. A second and third suit were filed in November 2011 and January 2013, respectively, in Multnomah County Circuit Court in Oregon by 14 former and 13 former students, respectively, also alleging abuse. The plaintiffs seek a total of $23 million in relief in the second suit and a total of $19.5 million in relief in the third suit. CRC, Aspen and MBA are among the defendants in these two suits. In February 2014, approximately 15 additional students notified MBA of claims but have yet to file a lawsuit. We and the other defendants intend to defend vigorously the pending lawsuits. In consultation with counsel and based on our preliminary investigation into the facts alleged, we believe these cases are without merit. However, at this time, we are unable to predict the outcome of the lawsuit, the possible loss or range of loss, if any, after consideration of the extent of insurance coverage associated with the resolution of the lawsuit or any potential effect it may have on us or our operations. On May 10, 2012, Nautilus Insurance Corporation filed a complaint against CRC Health Group Inc. and certain related entities seeking declaratory relief in the federal district court in Portland, Oregon. The Complaint seeks a judicial determination as to whether the Nautilus general and healthcare professional liability insurance policies provide coverage for these suits against MBA and asks the court to enter judgment that the policies are null and void, or alternatively that the policies do not cover these specific lawsuits, and to declare that Nautilus has no

- 30 -

duty to defend or indemnify MBA, Aspen or CRC. Although discovery has been stayed, the judge has provided Nautilus leave to file for summary judgment on certain matters. In consultation with counsel and based on our preliminary review of the matters alleged, we believe this suit is without merit and we are vigorously defending the matter. Although the Company believes the amounts reserved are adequate based on currently available information, the estimation process involves a considerable amount of judgment by management and the ultimate amounts could vary materially.

In a complaint filed in August 2011, a suit against our New Life Lodge facility was brought by Kathy Mauk as administrator of the estate of Lindsey Poteet a/k/a Lindsey Richardson, deceased and on behalf of the wrongful death beneficiary of Lindsey Poteet a/k/a Lindsey Richardson, Arwen Richardson, vs. CRC Health Tennessee, Inc. dba New Life Lodge and CRC Health Group, Inc. dba New Life Lodge. The suit alleged negligence and medical malpractice resulting in wrongful death and sought a total $32.0 million in compensatory and punitive damages. This suit was settled at mediation in December 2013 within the amounts previously reserved.

In a complaint filed in December 2012, a suit against our New Life Lodge facility was brought by Charity Comage as administrator of the estate of and on behalf of Savon Kinney, deceased vs CRC Health Tennessee, Inc. dba New Life Lodge and CRC Health Group, Inc. dba New Life Lodge, American Behavioral Consultants, LLC and Holly Liter, APN. This suit alleges negligence and medical malpractice resulting in the wrongful death and seeking a total $14.5 million in compensatory and punitive damages. American Behavioral Consultants, LLC served as an independent contractor for New Life Lodge and Ms. Holly Liter was an employee of American Behavioral Consultants, LLC. In a complaint filed in June 2013, a suit against our New Life Lodge was brought by Penny Bryant, mother of Patrick Bryant, deceased, vs. CRC Health Tennessee, Inc. and Jonathan Butler, M.D. This suit was originally filed in 2011 and then dismissed without prejudice in October 2012 and was re-filed in June 2013. This suit alleges negligence resulting in the wrongful death of Patrick Bryant and seeks a total of $13.0 million in compensatory and punitive damages. We intend to defend vigorously these lawsuits. In consultation with counsel and based on our preliminary investigation into the facts alleged, we believe these cases are without merit. Although the Company believes the amounts reserved are adequate based on currently available information, the estimation process involves a considerable amount of judgment by management and the ultimate amounts could vary materially.

In 2013, our New Life Lodge facility responded to a civil investigative demand (“CID”) from the Office of the Attorney General of the State of Tennessee inquiring about possible false claims for payment related to services provided to TennCare recipients for the period 2006 to 2011. The United States Department of Justice participated in this investigation and has also requested information from New Life Lodge. While the Company disputes the validity of the allegations in this suit, in order to avoid the distraction of a protracted legal process, the Company has agreed to settle this lawsuit joined by the State of Tennessee and the US Department of Justice related to the services provided in the past to TennCare patients who sought care at New Life Lodge between 2006 and 2011 for a total of $9.25 million. This settlement amount had been accrued as of December 31, 2013 and was paid in April 2014.

We are involved in other litigation and regulatory investigations arising in the ordinary course of business. After consultation with legal counsel, management estimates that these matters will be resolved without material adverse effect on our future financial position or results from operations and cash flows, except as discussed above. As of December 31, 2013 and 2012, accruals for legal matters totaled $12.4 million and $1.7 million, respectively, and were included in “accrued expenses” in the Condensed Consolidated Balance Sheets.

NOTE 11. REDEEMABLE NONCONTROLLING INTEREST

The Company owned a 75 percent interest in an entity. The 25 percent noncontrolling interest holder had the unilateral right to require the Company to redeem the noncontrolling interest at a price to be calculated pursuant to the terms and conditions of the operating agreement. In 2011, the Company accrued $0.9 million for the estimated amount to redeem the noncontrolling interest, resulting in “net income attributable to noncontrolling interest”. In 2012, the Company redeemed the noncontrolling interest for $0.5 million, resulting in “net loss attributable to noncontrolling interest” of $0.4 million.

- 31 -

NOTE 12. STOCKHOLDERS’ EQUITY

The Company’s Amended and Restated Certificate of Incorporation authorizes it to issue 55,555,555 shares of $0.001 par value common stock, of which 50,000,000 shares and 5,555,555 shares have been designated as Class A common stock and Class L common stock, respectively.

Voting — The common stock shall have and possess all powers and voting and other rights pertaining to the stock of the Company. Holders of the Class A and Class L common stock shall vote together as a single class, with each share being entitled to one vote on all matters to be voted on by the stockholders.

Distributions — First, holders of Class L common stock shall be entitled to receive from all Liquidation Distributions (all distributions made by the corporation on liquidation or following a sale of all or substantially all of the business or assets of the company) an amount equal to the Class L Base Amount, an amount equal to $81.00. Thereafter, all shares of Common Stock, as a single class shall be entitled to receive all remaining Liquidation Distributions pro rata based on the number of shares outstanding; provided however that the Class L shall have been deemed to convert into a number of shares of Class A Common Stock sufficient to generate an internal rate of return thereon equal to twelve percent (12%) per annum, compounded quarterly. Such internal rate of return shall treat each share as having been paid for on February 6, 2006 and each distribution with respect to the Class L common stock as having been made on the date paid by the Company. As of December 31, 2013, no amounts have been accrued for distribution to Class L common stock, as there have been no distributions to holders of the Company’s common stock. After the full required amount of distributions have been made to Class L common stockholders as previously described, all holders of the shares of common stock, as a single class, shall thereafter be entitled to receive all remaining distributions pro rata based on the number of outstanding shares of common stock. For the purpose of this distribution each share of Class L common stock shall be deemed to have been converted into Class A shares under the applicable conversion formula.

Mandatory Conversion — Upon closing of a public offering or in connection with the transfer or sale of the Class L common stock (a “Realization Event”), each outstanding share of Class L common stock shall automatically convert into a number of shares of Class A common stock under the applicable conversion formula.

In connection with the Extended PIK Loan, the Company issued warrants to Extending PIK Loan lenders to purchase 124,705 units of common stock at an exercise price of $72.00 per unit. The warrants expire in January 2018. The warrants were valued using the Black Scholes option-valuation model based on the following assumptions: risk-free interest rate of 2.81%, expected term of 7 years, annual volatility of 43.3%, and no dividend yield. The fair value of these warrants was $4.4 million and was recognized as a debt discount and is being amortized to interest expense over the term of the agreement, using the effective interest-rate method. The amortization expense for the year ended December 31, 2013 was $0.9 million.

NOTE 13. STOCK-BASED COMPENSATION

Description of Share-Based Plans

2006 Executive Incentive Plan, 2006 Management Incentive Plan and 2007 Incentive Plan

On February 6, 2006 the Group adopted the 2006 Executive Incentive Plan (the “Executive Plan”) and the 2006 Management Incentive Plan (the “Management Plan”) and on September 7, 2007, the Group adopted the 2007 Incentive Plan (the “Incentive Plan”). The Company refers to the Executive Plan, Management Plan and Incentive Plan collectively as the “Plans.” The Plans provide for options to purchase Group stock by the Company’s key employees, directors, consultants and advisors. Options granted under the Plans may be either incentive or non-incentive stock options. As of December 31, 2013, only non-incentive options (non-qualified under Internal Revenue Code 422) have been awarded under the Plans. Options granted under the Plans represent units. One unit consists of nine shares of class A and one share of class L common stock of the Group.

- 32 -

Options under the Plans may be granted for periods of up to ten years at an exercise price generally not less than fair market value of the shares subject to the award, determined as of the award date.

Options granted under the Executive Plan and Incentive Plan vest in tranches. Tranche 1 options represent 50% of an option grant and Tranche 2 and Tranche 3 represent the remaining 50% of the option grant. Tranche 1 options vest and become exercisable at the rate of 20% one year from the date of grant and 10% at six-month increments thereafter or, if earlier, 100% on a change of control as defined in the Plans. Options issued under Tranche 2 and Tranche 3 vest and become exercisable upon achievement of both a performance and a market condition, as defined in the Executive and Incentive Plans. In order to vest, the recipient must continue to provide service as an employee through the vesting date.

Options granted under the Management Plan vest and become exercisable over five years as follows: 20% one year from the date of grant and 10% at six-month increments thereafter or, if earlier, 100% on a change of control, as defined in the Management Plan.

Beginning in 2011, additional options were granted to senior executives under the Incentive Plan. The options vest in two tranches as follows: Tranche 1 options vest and become exercisable at the rate of 20% one year from the date of grant and 10% at six-month increments thereafter or, if earlier, 100% on a change of control as defined in the Plans; Tranche 2 options vest and become exercisable upon achievement of both a performance and a market condition, as defined I the Incentive Plan. In order to vest, the recipient must continue to provide service as an employee through the vesting date. Tranche 1 and Tranche 2 options each represent 50% of the option grant.

A maximum of 5,734,053 shares of Class A common stock of the Group and 637,117 shares of Class L common stock of the Group may be granted under the Plans.

Stock Option Expense Measurement and Recognition

The Company measures and recognizes expense for all stock-based payment awards, including employee stock options, granted after January 1, 2006, based on the grant-date fair value. Management estimates grant date fair using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods on a straight-line basis in the consolidated statements of operations. In addition, for the options that vest upon the achievement of performance conditions, the Company recognizes compensation expense only if achievement of such performance conditions is probable. For awards that are subject to both a performance and market condition, compensation expense is recognized over the longer of the implicit service period associated with the performance condition or the initial derived service period associated with the market condition.

Stock-based compensation expense is based on awards ultimately expected to vest net of an estimated forfeiture rate. Forfeitures are estimated at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated forfeiture rate was 4%, 6%, 5% for the years ended December 31, 2013, 2012, and 2011, respectively.

The Company recognizes the cash flows resulting from the tax benefits created by tax deductions in excess of the compensation cost as financing cash flows.

Valuation of Stock-Based Awards

The Company estimated the fair value of stock options granted in 2013, 2012, and 2011 using a binomial Monte Carlo simulation. The weighted average grant date fair value of units granted during the years ended December 31, 2013, 2012, and 2011 were $45.69, $39.06, and $24.77 per unit, respectively.

- 33 -

The fair value of stock-based payment awards was estimated using the following assumptions:

	Year Ended December 31, 2013			Year Ended December 31, 2012			Year Ended December 31, 2011
Binomial Monte Carlo simulation
Expected asset volatility		20	%		20	%		15	%
Dividend yield		0	%		0	%		0	%
Risk-free interest rate		1.90	%		1.62	%		2.14 - 3.65	%

• Expected asset volatility utilized for the units granted is based on the historical volatility of comparable public companies for periods corresponding to the expected term of the awards.

• No dividends are expected to be paid over the option term.

• The risk-free rate used for options granted is based on the implied yield on U.S. Treasury constant maturities issued with a term equal to the expected term of the options.

Stock-Based Compensation Expense

Compensation expense related to the stock options granted by the Group is being recorded on the Company’s consolidated financial statements, as substantially all grants have been made to employees of the Company. For the years ended December 31, 2013, 2012, and 2011, the Company recognized stock-based compensation expense of less than $0.1 million, $2.7 million, and $1.4 million, respectively, within salaries and benefits on the consolidated statements of operations. The variations in stock-based compensation expense from year to year are due to the Company’s assessments of the likelihood that certain options will meet performance conditions prior to their expiration.

As of December 31, 2013, $11.3 million of total unrecognized compensation, net of estimated forfeitures of $0.5 million, is expected to be recognized over a weighted-average period of 2.91 years if all the service, performance and market conditions are met under the provisions of the option plans. During the years ended December 31, 2013, 2012, and 2011, 333,867 shares, 408,888 shares, and 269,349 shares vested with an aggregate grant date fair value of $1.1 million, $1.2 million, and $1.3 million, respectively.

Stock Option Activity under the Plans

During the year ended December 31, 2013, the Group granted 86,550 units, which represent 778,950 options to purchase Class A common stock and 86,550 options to purchase Class L common stock. Activity under the Plans for the year ended December 31, 2013 is summarized below:

	Option (In Shares)			Weighted- Average Exercise Price Per Share		Weighted- Average Grant Date Fair Value		Weighted- Average Remaining Contractual Term (In Years)
Balance at December 31, 2012		6,461,533		$	7.29				5.58
Granted		865,500			8.04	$	4.57		9.16
Exercised		—
Forfeited/cancelled/expired		(602,996	)		8.94	$	4.25
Outstanding — December 31, 2013		6,724,037		$	7.22				5.13
Exercisable — December 31, 2013		3,120,647		$	6.45				3.22
Exercisable and expected to be exercisable		6,387,835		$	7.22				5.13

- 34 -

As of December 31, 2013, the aggregate intrinsic value of options outstanding, exercisable, and outstanding and expected to be exercised was $10.5 million, 10.1 million, and $7.1 million, respectively. The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the fair value of the Group’s shares as of December 31, 2013. At December 31, 2013, the Company had 3,603,390 unvested option shares with per-share, weighted average grant date fair values of $3.63.

The aggregate intrinsic value of share options exercised since inception under equity compensation plans was $2.8 million, $2.8 million, and $2.0 million as of December 31, 2013, 2012, and 2011, respectively.

The following table presents the composition of options outstanding and exercisable as of December 31, 2013.

Options Outstanding							Options Exercisable
Range of Exercise Prices	Number of Shares		Weighted Average Remaining Contractual Term (years)		Weighted Average Exercise Price		Number of Shares		Weighted Average Exercise Price
$0.02 - $ 0.32		3,749,917		6.67	$	0.19		1,284,592	$	0.16
$1.00 - $3.30		2,301,715		2.62		1.05		1,523,985		1.05
$7.89 - $17.62		87,845		2.11		8.05		87,845		8.05
$69.64 - $98.16		584,560		5.59		76.45		224,225		78.83
Total		6,724,037		5.13	$	7.22		3,120,647	$	6.45

NOTE 14. RELATED PARTY TRANSACTIONS

The Company maintains a stockholders agreement with its security holders. The stockholders agreement contains agreements among the parties with respect to the election of the Company’s directors and the directors of the Parent, restrictions on the issuance or transfer of shares, including tag-along rights and drag-along rights, other special corporate governance provisions (including the right to approve various corporate actions), registration rights (including customary indemnification provisions) and call options. Three of the Company’s five directors are employees of Bain Capital, the Company’s principal stockholder.

The Company maintains a management agreement with an affiliate of Bain Capital Partners, LLC pursuant to which such entity or its affiliates will provide management services. Pursuant to such agreement, an affiliate of Bain Capital Partners, LLC will receive an aggregate annual management fee of $2.0 million and reimbursement in connection with the provision of services pursuant to the agreement. The management agreement has a five year, evergreen term; however, in certain circumstances, such as an initial public offering or change of control of the Group, the Company may terminate the management agreement and buy out its remaining obligations under the agreement to Bain Capital Partners, LLC and affiliates. In addition, the management agreement provides that an affiliate of Bain Capital Partners, LLC may receive fees in connection with certain subsequent financing and acquisition transactions.

The management agreement includes customary indemnification provisions in favor of Bain Capital Partners, LLC and its affiliates.

The Company, under this agreement, incurred management fees of $2.2 million, $3.0 million, and $2.5 million during the years ended December 31, 2013, 2012, and 2011, respectively, which is included in facilities and other operating costs in the Company’s consolidated statements of operations.

- 35 -

NOTE 15. RESTRUCTURING

The Company’s historical restructuring reserves are the result of consolidation and exit activities related to excess or under-performing facilities and consist primarily of future rental payments and related facility maintenance costs, net of estimated sublease income. These cash payments are expected to continue through fiscal 2020. As of December 31, 2013, the remaining reserve totaled $19.2 million (of which $15.3 million is included in long-term liabilities of discontinued operations and facilities held for sale) and is summarized and presented below (in thousands):

Total restructuring reserve at December 31, 2010	$	6,258
Expenses		9,736
Cash payments		(6,111	)
Total restructuring reserve at December 31, 2011		9,883
Expenses		1,507
Cash payments		(2,096	)
Total restructuring reserve at December 31, 2012		9,294
Expenses		14,449
Cash payments		(3,193	)
Reclassification to accrued expenses (1)		(1,338	)
Total restructuring reserve at December 31, 2013	$	19,212

⁽¹⁾  The restructuring reserve balance and associated activity represents a purchase accounting liability that was accrued in connection with a 2009 acquisition. This amount was inappropriately included in the restructuring reserve Note disclosure as of December 31, 2009 and thereafter. As of December 31, 2013 and 2012, the purchase accounting liability is appropriately included in “accrued expenses” in the Condensed Consolidated Balance Sheet.

NOTE 16. DISCONTINUED OPERATIONS

During the year ended December 31, 2013, the Company classified 23 facilities as discontinued operations. These facilities were either sold, closed, met the cease of use criteria, or met the held for sale criteria as of December 31, 2013. During the years ended December 31, 2012 and 2011, the Company classified 2 and 14 facilities as discontinued operations, respectively.

On January 31, 2014, the Company sold eight Wellspring Camps. In connection with the sale, the Company recorded a $1.7 million non-cash impairment charge related to other intangible assets, and a $0.1 million non-cash impairment charge related to property and equipment for the year ended December 31, 2013. This transaction met the held for sale criteria as of December 31, 2013 and its historical operations, including the non-cash asset impairment charges, have been reclassified into discontinuing operations for all periods presented in the Consolidated Statement of Operations.

The Company sold three facilities in April 2014. In connection with the sale, the Company recorded a $10.6 million non-cash impairment charge related to other intangible assets, and a $0.6 million non-cash impairment charge related to property and equipment for the year ended December 31, 2013. This transaction met the held for sale criteria at December 31, 2013 and its historical operations, including the non-cash asset impairment charges, have been reclassified into discontinuing operations for all periods presented in the Consolidated Statement of Operations.

In 2014, the Company classified two additional facilities as discontinued operations. The Company closed one facility in March 2014 and sold one facility in August 2014 (see Note 17). Net client service revenues for these two facilities were $6.4 million, $8.2 million, and $8.5 million in 2013, 2012 and 2011, respectively. Income (loss) before income taxes for these two facilities were ($0.4) million, $0.7 million, and $0.4 million in 2013, 2012 and 2011, respectively.

- 36 -

The results of operations for all facilities classified as discontinued operations including those discussed above, are summarized below (in thousands):

	Years Ended December 31,
	2013			2012			2011
Net client service revenues	$	45,942		$	68,882		$	82,440
Operating expenses		68,275			70,563			92,120
Goodwill and asset impairment		24,637			3,361			9,211
Interest expense		(7	)		(2	)		(6	)
(Gain) loss on disposal of discontinued operations		(567	)		273			—
Loss before income taxes		(46,396	)		(5,313	)		(18,885	)
Income tax expense (benefit)		(2,336	)		6,136			9,654
Loss from discontinued operations	$	(44,060	)	$	(11,449	)	$	(28,539	)

Asset impairments consist of the following for the years ended December 31, 2013, 2012 and 2011.

	Asset Impairments
	2013		2012		2011
Referral network	$	9,304	$	728	$	2,860
Regulatory licenses		5,036		—		688
Accreditations		4,808		566		1,769
Curriculum		2,065		183		610
Trademarks and trade names		2,072		1,338		1,470
Property and equipment		1,352		546		1,814
Total	$	24,637	$	3,361	$	9,211

NOTE 17. SUBSEQUENT EVENTS

The Company performed an evaluation of subsequent events from the balance sheet date of December 31, 2013 through (i) April 30, 2014, the date the consolidated financial statements were available to be issued and (ii) January 27, 2015, the date the consolidated financial statements were available to be reissued, and concluded that there are no additional events requiring recording or disclosure in the consolidated financial statements, except as described below.

Habit Acquisition

On February 28, 2014, the Company acquired all of the issued and outstanding equity of Habit Holdings, Inc. (“Habit”) for an aggregate cash purchase price of approximately $58.0 million, subject to a working capital adjustment to be calculated within 90 days. Habit consists of 20 comprehensive treatment centers and 2 mobile units primarily in Massachusetts and several nearby states. The Purchase Agreement contains customary representations and warranties and covenants. Subject to certain limitations, the Sellers have agreed to indemnify the Company, and the Company has agreed to indemnify the Sellers, for certain breaches of representations, warranties and covenants, and other specified matters.

Also, on February 28, 2014, pursuant to an amended credit agreement, the Company obtained incremental term loans in the aggregate principal amount of $50.0 million (the “Term B-4 Loans”), the proceeds of which, together with other funds available to the Company, were used to pay the consideration for the acquisition. All term loans under the Company’s senior secured credit facility will mature on November 16, 2015 (the “Maturity Date”).

- 37 -

March 28, 2014 Refinancing

On March 28, 2014, the Company completed a refinancing and repaid all of its outstanding indebtedness under its existing senior secured credit agreement (term loans and revolving line of credit) and its senior subordinated notes and entered into new long-term debt agreements (see description below). As a result, the Company recorded a loss on debt extinguishment of $11.6 million, related to the write-off of deferred financing costs and unamortized discounts in 2014.

As a result of the refinancing:

• new borrowings of $775.0 million were entered into, comprised of $475.0 million of First Lien Term Loans and $300.0 million of Second Lien Term Loans,

• existing term loans of $383.8 million were repaid in full,

• existing senior subordinated notes of $177.3 million were repaid in full,

• additional term loan entered into on February 28, 2014 for the purchase of Habit of $50.0 million (see above) was repaid in full,

• the then outstanding revolving line of credit of $34.0 million was repaid,

• $84.3 million on the payment in kind loan was repaid,

• accrued interest related to the existing debt obligations of $6.3 million was paid, and

• debt issuance costs and discounts incurred totaled $31.3 million, including $7.8 million paid to an affiliate of Bain Capital Partners LLC, the Company’s principal stockholder.

A summary and key terms of the new indebtedness are as follows.

First Lien Credit Agreement and Second Lien Credit Agreements

First Lien Term Loans

Under the First Lien Credit Agreement, the Company borrowed an aggregate principal amount of $475.0 million of new First Lien Term Loans that mature on March 28, 2021 (the “First Lien Term Loans”). The First Lien Term Loans were issued with an original issue discount of 1.00% or $4.75 million which is being amortized over the term of the First Lien Term Loans using the effective interest rate method.

Interest on these First Lien Term Loans is payable monthly or quarterly, depending on interest option selected, at: (i) for LIBOR loans for any interest period, a rate per annum equal to the LIBOR rate as determined by the administrative agent (but not less than 1.00%), plus an applicable margin of 4.25%, and (ii) for base rate loans, a rate per annum equal to the greater of (x) the prime rate of the administrative agent, (y) the federal funds rate plus one-half of 1.00%, and (z) the LIBOR rate applicable to a one-month interest period plus 1.00% (but, in each case, not less than 2.00%), plus an applicable margin of 3.25%.

The First Lien Term Loans are payable in quarterly principal installments of 0.25% of the aggregate First Lien Term Loans on the last Business Day of each March, June, September and December, beginning on the last business day of June 2014, with the remainder due on the maturity date of March 28, 2021.

The First Lien Term Loans are subject to a 1.00% prepayment premium to the extent they are refinanced, or the terms thereof are amended, in either case, for the purpose of reducing the applicable yield with respect thereto, in each case prior to the first anniversary of the Refinancing.

The Company is required to apply a certain portion of its excess cash to the principal amount of the First Lien Term Loans on an annual basis, commencing with the Fiscal Year ending December 31, 2015. Excess cash under the Company’s First Lien Credit Agreement is defined as net income attributable to the Company adjusted for certain cash and non-cash items. Required payments, if any, are due in April of the subsequent year.

- 38 -

Revolving Line of Credit

At March 28, 2014, under the First Lien Credit Agreement, the Company had aggregate borrowing capacity for revolving credit commitments of $65.0 million which mature on March 28, 2019. Interest is payable monthly or quarterly, depending on interest option selected, at (i) for LIBOR loans for any interest period, a rate per annum equal to the LIBOR rate as determined by the administrative agent, plus an applicable margin of 4.25%, 4.00% and 3.75%, based upon the Company’s first lien net leverage ratio being within certain defined ranges, and (ii) for base rate loans, a rate per annum equal to the greater of (x) the prime rate of the administrative agent, (y) the federal funds rate plus one-half of 1.00% and (z) the LIBOR rate applicable to a one-month interest period plus 1.00%, plus an applicable margin of 3.25%, 3.00% or 2.75%, based upon the Company’s first lien net leverage ratio being within certain defined ranges. Unused line fees are payable quarterly at a rate equal to 0.50% or 0.375%, based upon the Company’s first lien net leverage ratio being within certain defined ranges.

The Company’s First Lien Term Loans and Revolving Line of Credit are guaranteed by the Company’s Parent and substantially all of the Company’s current and future wholly-owned domestic subsidiaries, and secured by substantially all of their existing and future property and assets, and secured by a pledge of the Company’s capital stock and the capital stock of the Company’s domestic wholly-owned subsidiaries and up to 65% of the capital stock of first-tier foreign subsidiaries. The Company’s First Lien Credit Agreement requires the Company to comply on a quarterly basis with certain financial and other covenants, including a maximum total net leverage ratio test.

Second Lien Term Loans

On March 28, 2014, under the Second Lien Credit Agreement, the Company borrowed an aggregate principal amount of $300.0 million of new Second Lien Term Loans that mature on September 28, 2021 (the “Second Lien Term Loans”). The Second Lien Term Loans were issued with an original issue discount of 2.00% or $6.0 million which is being amortized over the term of the Second Lien Term Loans using the effective interest rate method.

Interest on these Second Lien Term Loans is payable monthly or quarterly, depending on interest option selected, at: (i) for LIBOR loans for any interest period, a rate per annum equal to the LIBOR rate as determined by the administrative agent (but not less than 1.00%), plus an applicable margin of 8.00%, and (ii) for base rate loans, a rate per annum equal to the greater of (x) the prime rate of the administrative agent, (y) the federal funds rate plus one-half of 1.00%, and (z) the LIBOR rate applicable to a one-month interest period plus 1.00% (but, in each case, not less than 2.00%), plus an applicable margin of 7.00%.

The Second Lien Term Loans are subject to a 3.00% prepayment premium to the extent they are repaid prior to the first anniversary of the Refinancing, a 2.00% prepayment premium to the extent they are repaid on or after the first anniversary and prior to the second anniversary of the Refinancing, and a 1.00% prepayment premium to the extent they are repaid on or after the second anniversary and prior to the third anniversary of the Refinancing. The foregoing prepayment premiums shall also apply if the Second Lien Term Loans are amended for the purpose of reducing the applicable yield with respect thereto, in each case prior to the third anniversary of the Refinancing.

After repayment and termination of the loans under the First Lien Credit Agreement, the Company is required to apply a certain portion of its excess cash to the principal amount of the Second Lien Term Loans on an annual basis, commencing with the Fiscal year ending December 31, 2015. Excess cash under the Company’s Second Lien Credit Agreement is defined as net income attributable to the Company adjusted for certain cash and non-cash items. Required payments, if any, are due in April of the subsequent year.

The Company’s First Lien Term Loans, Revolving Line of Credit and Second Lien Term Loans are guaranteed by the Company’s Parent and substantially all of the Company’s current and future wholly-owned domestic subsidiaries, and secured by substantially all of their existing and future property and assets, and secured by a

- 39 -

pledge of the Company’s capital stock and the capital stock of the Company’s domestic wholly-owned subsidiaries and up to 65% of the capital stock of first-tier foreign subsidiaries. The Company’s First Lien Term Loans, Revolving Line of Credit and Second Lien Credit Agreement require the Company to comply on a quarterly basis with certain financial and other covenants, including a maximum total net leverage ratio test.

Acadia Healthcare Company, Inc. Acquisition of the Company

On October 29, 2014, the Company entered into a definitive agreement to be acquired by Acadia Healthcare Company, Inc. (“Acadia”). Total consideration for the acquisition will be approximately $1.2 billion, consisting of up to approximately 6.3 million shares of Acadia’s common stock and the assumption of the Company’s debt. The transaction is expected to close in the first quarter of 2015, and is subject to regulatory review and other normal closing conditions.

Additional Discontinued Operations

The Company closed one facility in March 2014 and recognized a loss of $0.6 million related to the closure. The Company sold another facility in August 2014 and recognized a loss of $2.2 million related to the sale. The Consolidated Statements of Operations have been reclassified for all periods presented to reflect the presentation of these two facilities as discontinued operations (see Notes 2 and 16). During 2014, the Company completed the sale of the Wellspring camps and four Youth facilities, which were classified as held for sale at December 31, 2013. The Company recorded a loss of $0.9 million in 2014 related to these sales.

Legal Matters

The Company settled the MBA claims and the litigation with Nautilus Insurance Corporation (see Note 10) in the second and third quarters of 2014 within the amounts previously reserved at December 31, 2013.

In 2012, the U.S. Department of Justice (“DOJ”) / Drug Enforcement Administration (“DEA”) issued subpoenas to six (6) clinics owned by the Company, requiring the Company to provide certain books, records and papers related to the practice by such clinics to accept and destroy surrendered medications. In May 2014, the Company received a Notice of Hearing for such clinics requesting an informal hearing at the offices of the DEA. The DOJ / DEA allege that the Company failed to keep proper records regarding the return and destruction of surrendered medications and failed to properly execute certain record keeping forms. The Company participated in the hearing and as a result is currently negotiating a memorandum of agreement to resolve the administrative part of these alleged recordkeeping violations. The DOJ has also made a civil penalty demand of $7 million in regard to the same alleged record keeping violations. We intend to defend vigorously these allegations. In consultation with counsel and based on our preliminary investigation into the facts alleged, the Company maintains that it has certain defenses to these allegations. Although the Company believes the amounts reserved are adequate based on currently available information, the estimation process involves a considerable amount of judgment by management and the ultimate amounts could vary materially.

*****

- 40 -

EX-99.3

Exhibit 99.3

CRC Health Group, Inc.

Condensed Consolidated Financial Statements as of September 30, 2014 and

December 31, 2013 and for the nine months ended September 30, 2014 and 2013

CRC Health Group, Inc.

Table of Contents

Condensed Consolidated Balance Sheets as of September 30, 2014 and December 31, 2013 (Unaudited)	2
Condensed Consolidated Statements of Operations for the nine months ended September  30, 2014 and 2013 (Unaudited)	3
Condensed Consolidated Statements of Comprehensive Loss for the nine months ended September  30, 2014 and 2013 (Unaudited)	4
Condensed Consolidated Statements of Cash Flows for the nine months ended September  30, 2014 and 2013 (Unaudited)	5
Notes to Condensed Consolidated Financial Statements	6-16

1

CRC HEALTH GROUP, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

SEPTEMBER 30, 2014 AND DECEMBER 31, 2013

(In thousands)

	September 30, 2014			December 31, 2013
Assets
Current assets:
Cash and cash equivalents	$	21,112		$	15,559
Accounts receivable, net		49,263			37,124
Prepaid expenses		5,770			4,393
Other current assets		2,368			1,980
Income taxes receivable		7,375			4,717
Current assets of discontinued operations and facilities held for sale		389			4,589
Total current assets		86,277			68,362
Property and equipment, net		128,851			126,467
Goodwill		559,613			519,103
Other intangible assets, net		266,639			251,699
Other assets, net		20,425			7,091
Total assets	$	1,061,805		$	972,722
Liabilities and stockholders’ equity (deficit)
Current liabilities:
Accounts payable	$	5,841		$	4,739
Accrued payroll and related expenses		22,777			18,427
Accrued interest		7,412			9,945
Accrued expenses		9,611			21,299
Current portion of long-term debt		4,709			538
Deferred revenue		5,713			5,183
Deferred income taxes		202			202
Other current liabilities		926			827
Current liabilities of discontinued operations and facilities held for sale		5,138			8,961
Total current liabilities		62,329			70,121
Long-term debt		874,669			770,749
Other long-term liabilities		11,419			11,597
Long-term liabilities of discontinued operations and facilities held for sale		13,658			16,067
Deferred income taxes		137,835			130,311
Total liabilities		1,099,910			998,845
Commitments and contingencies
Stockholders’ equity (deficit)		(38,105	)		(26,123	)
Total liabilities and stockholders’ equity (deficit)	$	1,061,805		$	972,722

See notes to condensed consolidated financial statements

2

CRC HEALTH GROUP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013

(In thousands)

	Nine Months Ended September 30,
	2014			2013
Net client service revenues	$	340,255		$	309,449
Operating expenses:
Salaries and benefits		157,792			140,044
Facilities and other operating costs		99,917			96,128
Provision for doubtful accounts		5,718			5,674
Depreciation and amortization		15,352			14,363
Asset impairment		1,089			—
Total operating expenses		279,868			256,209
Operating income		60,387			53,240
Interest expense		(54,455	)		(53,535	)
Loss on debt extinguishment		(11,622	)		—
Other income		—			744
Income (loss) from continuing operations before income taxes		(5,690	)		449
Income tax expense		254			1,261
Loss from continuing operations, net of tax		(5,944	)		(812	)
Loss from discontinued operations, net of tax		(6,602	)		(29,039	)
Net loss	$	(12,546	)	$	(29,851	)

See notes to condensed consolidated financial statements

3

CRC HEALTH GROUP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013

(In thousands)

	Nine Months Ended September 30,
	2014			2013
Net loss	$	(12,546	)	$	(29,851	)
Other comprehensive loss:
Net change in unrealized loss on cash flow hedges (net of tax benefit of $0 for both the nine months ended September 30, 2014 and 2013)		(163	)		(1	)
Comprehensive loss	$	(12,709	)	$	(29,852	)

See notes to condensed consolidated financial statements

4

CRC HEALTH GROUP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013

(In thousands)

	Nine Months Ended September 30,
	2014			2013
Cash flows from operating activities:
Net loss	$	(12,546	)	$	(29,851	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization		15,377			15,248
Accretion of non-cash interest on payment in kind loan		5,526			17,109
Amortization of debt discount and capitalized financing costs		3,899			4,242
Asset impairments		1,089			10,923
Loss on debt extinguishment		11,622			—
Loss on disposal of property and equipment		552			420
Loss on sale of discontinued operations		3,139			—
Provision for doubtful accounts		5,790			5,791
Stock-based compensation		1,944			(630	)
Deferred income taxes		(1,049	)		—
Changes in assets and liabilities:
Accounts receivable		(15,886	)		(9,858	)
Prepaid expenses		(1,193	)		(1,142	)
Income taxes receivable and payable		(2,645	)		232
Accounts payable		(275	)		628
Accrued liabilities		(12,409	)		12,499
Other current assets		(297	)		266
Other current liabilities		476			(1,503	)
Other long-term assets		257			914
Other long-term liabilities		(1,793	)		9,394
Net cash provided by operating activities		1,578			34,682
Cash flows from investing activities:
Additions of property and equipment		(11,344	)		(16,595	)
Proceeds from sale of property and equipment		75			36
Acquisition of business, net of cash acquired		(56,442	)		(140	)
Proceeds from sale of discontinued operations, net of cash disposed		1,064			—
Net cash used in investing activities		(66,647	)		(16,699	)
Cash flows from financing activities:
Borrowings of long-term debt		813,875			—
Repayment of long-term debt		(699,173	)		(5,618	)
Borrowings on revolving line of credit		15,000			15,000
Repayments on revolving line of credit		(34,000	)		(33,000	)
Capitalized financing costs		(23,595	)		(217	)
Repurchase of common stock		(1,419	)		(286	)
Proceeds from issuance of common stock		270			—
Other financing activities		(336	)		—
Net cash provided by (used in) financing activities		70,622			(24,121	)
Net increase (decrease) in cash and cash equivalents		5,553			(6,138	)
Cash and cash equivalents—beginning of period		15,559			19,058
Cash and cash equivalents—end of period	$	21,112		$	12,920

See notes to condensed consolidated financial statements

5

CRC HEALTH GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 1. OVERVIEW AND BASIS OF PRESENTATION

Overview

CRC Health Group, Inc. (“the Company”) is headquartered in Cupertino, California, and through its wholly owned subsidiaries provides rehabilitation and treatment services related to substance abuse, addiction diseases and other behavioral disorders.

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information required by accounting principles generally accepted in the United States of America for annual financial statements. The unaudited condensed balance sheet as of December 31, 2013 has been derived from our audited financial statements.

In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments, consisting of normal recurring and other adjustments (see Notes 3 and 9) , necessary to present fairly the financial position of the Company, its results of operations, and its cash flows. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto not included herein. The results of operations for the nine months ended September 30, 2014 and 2013 presented herein are not necessarily indicative of the results to be expected for the full fiscal year.

Principles of Consolidation—The Company’s condensed consolidated financial statements include the accounts of CRC Health Group Inc. and its consolidated subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates—Preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates.

Reclassifications: Discontinued Operations—The condensed consolidated statements of operations have been reclassified for all periods presented to reflect the presentation of closed or sold facilities as discontinued operations (see Note 12). Unless noted otherwise, discussions in the notes to the condensed consolidated financial statements pertain to continuing operations.

NOTE 2. ACQUISITION OF HABIT HOLDINGS, INC.

On February 28, 2014, the Company acquired all of the issued and outstanding equity of Habit Holdings, Inc. (“Habit”) for a cash purchase price of $58.0 million. Habit consists of 20 comprehensive treatment centers and 2 mobile units in Massachusetts and several nearby states. To fund the cash purchase price, the Company utilized approximately $50.0 million of new term loans entered into at such time. In connection with the new term loan, the Company incurred and recorded $1.9 million of deferred financing costs and debt discounts, of which $0.5 million was paid to an affiliate of Bain Capital Partner LLC, the Company’s principal stockholder.

6

The following table summarizes the allocation of the purchase price to the fair value of the assets acquired and the liabilities assumed (in thousands):

Current assets	$	4,065
Property and equipment		4,356
Goodwill		40,510
Intangible assets:
Trade name		6,890
Regulatory licenses		14,380
Unfavorable leases		(350	)
Current liabilities		(3,277	)
Deferred income taxes		(8,574	)
Total net assets acquired	$	58,000

The goodwill, trade name and regulatory licenses have indefinite useful lives. Approximately $13.6 million of the goodwill recognized in the acquisition is expected to be deductible for tax purposes.

The accompanying statement of operations for the nine months ended September 30, 2014 includes the results of operations of Habit for the period from March 1, 2014 to September 30, 2014. The Company incurred approximately $0.6 million of acquisition-related expenses which are included in facility and other operating costs in the Company’s condensed consolidated statements of operations for the nine months ended September 30, 2014.

NOTE 3. GOODWILL AND INTANGIBLE ASSETS

Changes to goodwill for the nine months ended September 30, 2014 are as follows (in thousands):

Balance as of January 1, 2014
Goodwill, gross	$	750,025
Accumulated goodwill impairment		(230,922	)
Total goodwill		519,103
Goodwill additions		40,510
Goodwill impairment		—
Balance as of September 30, 2014
Goodwill, gross		790,535
Accumulated goodwill impairment		(230,922	)
Total goodwill	$	559,613

7

Intangible Assets

Total intangible assets at September 30, 2014 and December 31, 2013 consist of the following (in thousands):

	September 30, 2014							December 31, 2013
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Intangible assets subject to amortization:
Referral network	$	3,598	$	(1,417	)	$	2,181	$	5,368	$	(1,912	)	$	3,456
Curriculum		529		(208	)		321		794		(283	)		511
Government contracts (including Medicaid)		34,967		(20,203	)		14,764		34,967		(18,455	)		16,512
Managed care contracts		14,400		(12,480	)		1,920		14,400		(11,400	)		3,000
Total intangible assets subject to amortization	$	53,494	$	(34,308	)	$	19,186	$	55,529	$	(32,050	)	$	23,479
Intangible assets not subject to amortization:
Trademarks and trade names							162,777							156,302
Certificates of need							41,955							42,784
Regulatory licenses							42,721							29,134
Total intangible assets not subject to amortization							247,453							228,220
Total intangible assets						$	266,639						$	251,699

For the nine months ended September 30, 2014, the Company recognized non-cash impairment charges of $0.3 million for trademarks and trade names and $0.8 million for certificates of need.

NOTE 4. LONG-TERM DEBT

Long-term debt as of September 30, 2014 and December 31, 2013 consists of the following (in thousands):

	September 30, 2014			December 31, 2013
Term debt—first lien, net of discount of $4,399	$	468,226		$	—
Term debt—second lien, net of discount of $5,600		294,400			—
Revolving line of credit		—			19,000
Term loans, net of discount of $1,748		—			382,056
Senior subordinated notes, net of discount of $550		—			176,746
Payment in kind loan, net of discount of $0 and $2,054 in 2013		116,752			193,485
Total debt		879,378			771,287
Less: current portion of long-term debt		(4,709	)		(538	)
Total long-term debt	$	874,669		$	770,749

March 28, 2014 Refinancing

On March 28, 2014, the Company completed a refinancing and repaid all of its outstanding indebtedness under its existing senior secured credit agreement (term loans and revolving line of credit) and its senior subordinated notes and entered into new long-term debt agreements (see description below). The refinancing transaction was accounted for as an extinguishment of the existing debt. As a result, the Company recorded a loss on debt extinguishment of $11.6 million, related to the write-off of deferred financing costs and unamortized discounts, in the nine months ended September 30, 2014.

8

As a result of the refinancing:

• new borrowings of $775.0 million were entered into, comprised of $475.0 million of First Lien Term Loans and $300.0 million of Second Lien Term Loans,

• existing term loans of $383.8 million were repaid in full,

• existing senior subordinated notes of $177.3 million were repaid in full,

• additional term loan entered into on February 28, 2014 for the purchase of Habit of $50.0 million (see Note 2) was repaid in full,

• the then outstanding revolving line of credit of $34.0 million was repaid,

• $84.3 million on the payment in kind loan was repaid,

• accrued interest related to the existing debt obligations of $6.3 million was paid, and

• debt issuance costs and discounts incurred totaled $31.3 million, including $7.8 million paid to an affiliate of Bain Capital Partners LLC, the Company’s principal stockholder.

First and Second Lien Credit Agreements

First Lien Term Loans—Under the First Lien Credit Agreement, the Company borrowed an aggregate principal amount of $475.0 million of new First Lien Term Loans that mature on March 28, 2021 (the “First Lien Term Loans”). The First Lien Term Loans were issued with an original issue discount of 1.00% or $4.75 million which is being amortized over the term of the First Lien Term Loans using the effective interest rate method.

Interest on these First Lien Term Loans is payable monthly or quarterly, depending on interest option selected, at: (i) for LIBOR loans for any interest period, a rate per annum equal to the LIBOR rate as determined by the administrative agent (but not less than 1.00%), plus an applicable margin of 4.25%, and (ii) for base rate loans, a rate per annum equal to the greater of (x) the prime rate of the administrative agent, (y) the federal funds rate plus one-half of 1.00%, and (z) the LIBOR rate applicable to a one-month interest period plus 1.00% (but, in each case, not less than 2.00%), plus an applicable margin of 3.25%.

The First Lien Term Loans are payable in quarterly principal installments of 0.25% of the aggregate First Lien Term Loans on the last Business Day of each March, June, September and December, beginning on the last business day of June 2014, with the remainder due on the maturity date of March 28, 2021.

The First Lien Term Loans are subject to a 1.00% prepayment premium to the extent they are refinanced, or the terms thereof are amended, in either case, for the purpose of reducing the applicable yield with respect thereto, in each case prior to the first anniversary of the Refinancing.

The Company is required to apply a certain portion of its excess cash to the principal amount of the First Lien Term Loans on an annual basis, commencing with the year ending December 31, 2015. Excess cash under the Company’s First Lien Credit Agreement is defined as net income attributable to the Company adjusted for certain cash and non-cash items. Required payments, if any, are due in April of the subsequent year.

Second Lien Term Loans—On March 28, 2014, under the Second Lien Credit Agreement, the Company borrowed an aggregate principal amount of $300.0 million of new Second Lien Term Loans that mature on September 28, 2021 (the “Second Lien Term Loans”). The Second Lien Term Loans were issued with an original issue discount of 2.00% or $6.0 million which is being amortized over the term of the Second Lien Term Loans using the effective interest rate method.

Interest on these Second Lien Term Loans is payable monthly or quarterly, depending on interest option selected, at: (i) for LIBOR loans for any interest period, a rate per annum equal to the LIBOR rate as determined by the

9

administrative agent (but not less than 1.00%), plus an applicable margin of 8.00%, and (ii) for base rate loans, a rate per annum equal to the greater of (x) the prime rate of the administrative agent, (y) the federal funds rate plus one-half of 1.00%, and (z) the LIBOR rate applicable to a one-month interest period plus 1.00% (but, in each case, not less than 2.00%), plus an applicable margin of 7.00%.

The Second Lien Term Loans are subject to a 3.00% prepayment premium to the extent they are repaid prior to the first anniversary of the Refinancing, a 2.00% prepayment premium to the extent they are repaid on or after the first anniversary and prior to the second anniversary of the Refinancing, and a 1.00% prepayment premium to the extent they are repaid on or after the second anniversary and prior to the third anniversary of the Refinancing. The foregoing prepayment premiums shall also apply if the Second Lien Term Loans are amended for the purpose of reducing the applicable yield with respect thereto, in each case prior to the third anniversary of the Refinancing.

After repayment and termination of the loans under the First Lien Credit Agreement, the Company is required to apply a certain portion of its excess cash to the principal amount of the Second Lien Term Loans on an annual basis, commencing with the year ending December 31, 2015. Excess cash under the Company’s Second Lien Credit Agreement is defined as net income attributable to the Company adjusted for certain cash and non-cash items. Required payments, if any, are due in April of the subsequent year.

Revolving Line of Credit—At March 28, 2014, under the First Lien Credit Agreement, the Company had aggregate borrowing capacity for revolving credit commitments of $65.0 million which mature on March 28, 2019. Interest is payable monthly or quarterly, depending on interest option selected, at (i) for LIBOR loans for any interest period, a rate per annum equal to the LIBOR rate as determined by the administrative agent, plus an applicable margin of 4.25%, 4.00% and 3.75%, based upon the Company’s first lien net leverage ratio being within certain defined ranges, and (ii) for base rate loans, a rate per annum equal to the greater of (x) the prime rate of the administrative agent, (y) the federal funds rate plus one-half of 1.00% and (z) the LIBOR rate applicable to a one-month interest period plus 1.00%, plus an applicable margin of 3.25%, 3.00% or 2.75%, based upon the Company’s first lien net leverage ratio being within certain defined ranges. Commitment fees are payable quarterly at a rate equal to 0.50% or 0.375%, based upon the Company’s first lien net leverage ratio being within certain defined ranges. As of September 30, 2014, the Company has not utilized the revolving line of credit.

The Company’s First Lien Term Loans, Second Lien Term Loans and Revolving Line of Credit are guaranteed by the Company’s Parent and substantially all of the Company’s current and future wholly-owned domestic subsidiaries, and secured by substantially all of their existing and future property and assets, and by a pledge of the Company’s capital stock and the capital stock of the Company’s domestic wholly-owned subsidiaries and up to 65% of the capital stock of first-tier foreign subsidiaries. The Company’s First Lien Term Loans, Second Lien Credit Agreement and Revolving Line of Credit require the Company to comply on a quarterly basis with certain financial and other covenants, including a maximum total net leverage ratio test. The Company was in compliance with the covenants as of September 30, 2014.

Payment in Kind Loan (“PIK” Loan)

As of September 30, 2014, the Company has a senior unsecured PIK loan to an affiliate of Bain Capital Partners, LLC of $116.8 million that matures on March 31, 2022. Interest is calculated at 12.00% until the maturity date. Accrued interest is added to the loan balance on April 1 and October 1 of each year. Approximately $7.2 million of accrued interest expense will be added to the principal balance on October 1, 2014.

10

Scheduled Principal Payments

At September 30, 2014, scheduled principal payments of total long-term debt, excluding the effects of the discount on the first and second lien, the PIK loan interest accretion and any annual excess cash payments that may be required are as follows (in thousands):

2014 (remaining 3 months)	$	1,187
2015		4,750
2016		4,750
2017		4,750
2018		4,750
Thereafter		869,190
Total	$	889,377

Interest Expense

The following table presents the components of interest expense (in thousands):

	Nine Months Ended September 30,
	2014			2013
Contractual interest on total debt	$	50,973		$	50,525
Amortization of debt discount and capitalized financing costs		3,738			3,549
Interest capitalized to property and equipment, net		(256	)		(539	)
Total interest expense	$	54,455		$	53,535

Capitalized Financing Costs

Costs to obtain the long-term debt were capitalized and amortized over the expected life of the debt instruments. Net capitalized financing costs are included in the Company’s Consolidated Balance Sheets in “other assets, net” and as of September 30, 2014 and December 31, 2013 were approximately $19.2 million and $6.6 million respectively. Amortization expense is included in the Company’s Consolidated Statements of Operations within interest expense as detailed above.

NOTE 5. DERIVATIVES AND HEDGING ACTIVITIES

Risk Management Objective of Using Derivatives

The Company is exposed to certain risk arising from both its business operations and economic conditions and manages economic risks, including interest rate, liquidity, and credit risk primarily by managing the amount, sources, and duration of its debt funding and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s investments and borrowings. However, the Company does not use derivatives for trading or speculative purposes and currently does not have any derivatives that are not designated as hedges.

Cash Flow Hedges of Interest Rate Risk

The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate

11

swaps and caps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges generally involve payments of interest expense based on a fixed interest rate instead of the existing variable rate. Interest rate caps designated as cash flow hedges involve the receipt of variable amounts from a counterparty if interest rates rise above the strike rate on the contract in exchange for an up-front premium.

The effective portion of changes in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in Accumulated Other Comprehensive Income and is subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings. During 2014, such derivatives were used to hedge the variable cash flows associated with existing (or anticipated) variable-rate debt. The ineffective portion of the change in fair value of the derivatives is recognized directly in earnings. During the nine months ended September 30, 2014 the Company recorded $0 of hedge ineffectiveness in earnings.

Amounts reported in Accumulated Other Comprehensive Income related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. During the period September 30, 2014 to September 30, 2015 the Company estimates that an additional $44,000 will be reclassified as an increase to interest expense.

In March 2014, in connection with refinancing its term loans, the Company terminated its interest rate swap and paid approximately $92,000 to the counterparty to settle the swap (including accrued interest). At the time of termination, there was a loss of approximately $69,000 deferred in Other Comprehensive Income related to this swap which was reclassified to interest expense.

Effective June 30, 2014, the Company entered into an interest rate cap agreement, whereby it paid an upfront premium of $1.1 million to limit the maximum LIBOR interest rate to 3.00% on a notional debt amount of $625 million. The interest rate cap agreement expires on March 31, 2017.

The table below presents the effect of the Company’s derivative financial instruments on the Condensed Consolidated Statement of Operations (in thousands):

Derivatives Designated as Cash Flow Hedges For the Nine Months Ended September 30,	Amount of Loss Recognized in OCI on Derivative (Effective Portion)						Location of Loss Reclassified from Accumulated OCI into Income (Effective Portion)		Amount of Loss Reclassified from Accumulated OCI into Income (Effective Portion)						Location of Loss Recognized in Income on Derivative (Ineffective Portion and Amount Excluded from Effectiveness Testing)	Amount of Loss Recognized in Income on Derivative (Ineffective Portion and Amount Excluded from Effectiveness Testing)
	2014			2013					2014			2013				2014		2013
Interest Rate Derivatives
Interest Rate Cap	$	(269	)	$	—			Interest Expense	$	—		$	—		Other Income/Expense	$	—	$	—
Pay-Fixed Swap		(26	)		(137	)				(132	)		(93	)			—		(43	)
Total	$	(295	)	$	(137	)			$	(132	)	$	(93	)		$	—	$	(43	)

Credit-risk-related Contingent Features

The Company has agreements with each of its derivative counterparties that contain a provision where the Company could be declared in default on its derivative obligations if repayment of the underlying indebtedness is accelerated by the lender due to the Company’s default on the indebtedness. As of September 30, 2014, the fair value of derivatives in a net liability position, related to these agreements was $0. If the Company had breached any of these provisions as of September 30, 2014, it could have been required to settle its obligations under the agreements at their termination value of $0.

12

NOTE 6. FAIR VALUE MEASUREMENTS

Assets and Liabilities Measured at Fair Value on a Recurring Basis

Derivative financial instruments

Currently, the Company uses interest rate caps to manage its interest rate risk. The fair value of interest rate cap was determined using the market standard methodology of discounting future cash receipts. Future cash receipts were based on the expectation of future interest rates (forward curves) derived from observed market interest rate curves and volatilities.

In measuring fair value, the Company incorporates credit valuation adjustments to appropriately reflect both its own nonperformance risk and the respective counterparty’s nonperformance risk. The Company also considered the impact of netting and any other applicable credit enhancements, such as collateral postings, thresholds, mutual puts, and guarantees. In conjunction with the FASB’s fair value measurement guidance, the Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.

Although the Company determined that the majority of the inputs used to value its derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by itself and its counterparties. However, as of September 30, 2014, the Company assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and determined that the credit valuation adjustments are not significant. As a result, the Company determined that its derivative valuations in their entirety are classified in Level 2 of the fair value hierarchy.

The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2014, aggregated by the level in the fair value hierarchy within which those measurements fall as of September 30, 2014 and December 31, 2013 (in thousands):

	Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)				Significant Other Observable Inputs (Level 2)				Significant Unobservable Inputs (Level 3)				Total Fair Value at As of
	September 30, 2014		December 31, 2013		September 30, 2014		December 31, 2013		September 30, 2014		December 31, 2013		September 30, 2014		December 31, 2013
Assets
Derivative Financial Instruments	$	0	$	0	$	741	$	0	$	0	$	0	$	741	$	0
Liabilities
Derivative Financial Instruments	$	0	$	0	$	0	$	106	$	0	$	0	$	0	$	106

NOTE 7. COMMITMENTS AND CONTINGENCIES

Legal Matters—In a complaint initially filed on July 6, 2011, and amended on August 25, 2011, in Multnomah County Circuit Court in Oregon, 17 former students of Mount Bachelor Academy, a previously closed therapeutic boarding school operated by our subsidiary Mount Bachelor Education Center, Inc. (“MBA”) alleged claims for intentional and negligent infliction of emotional distress, battery, breach of contract and negligence arising out of their treatment in certain programs at MBA. Our subsidiaries, Aspen Education Group, Inc. (“Aspen”) and MBA, are among the defendants in this litigation. The plaintiffs sought a total of $26.0 million in relief. A second and third suit were filed in November 2011 and January 2013, respectively, in Multnomah County Circuit Court in Oregon by 14 former and 13 former students, respectively, also alleging abuse. Those plaintiffs sought a total of $23.0 million in relief in the second suit and a total of $19.5 million in relief in the

13

third suit. CRC, Aspen and MBA are among the defendants in these two suits. In February 2014, approximately 15 additional students notified MBA of similar claims but had not filed a lawsuit. The above lawsuits and claims, along with an additional single-plaintiff lawsuit filed in September 2011 and claimant who threatened to file a lawsuit in May 2014, each of whom was represented by separate legal counsel, are collectively referred to as the MBA Claims. On May 10, 2012, Nautilus Insurance Corporation filed a complaint against CRC Health Group Inc. and certain related entities seeking declaratory relief in the federal district court in Portland, Oregon. The Complaint seeks a judicial determination as to whether the Nautilus general and healthcare professional liability insurance policies provide coverage for these suits against MBA and asks the court to enter judgment that the policies are null and void, or alternatively that the policies do not cover these specific lawsuits, and to declare that Nautilus has no duty to defend or indemnify MBA, Aspen or CRC. In the second and third quarter of 2014, the Company, or its applicable subsidiaries, settled the MBA Claims and the litigation with Nautilus Insurance Corporation within the amounts reserved.

In a complaint filed in August 2011, a suit against our New Life Lodge facility was brought by Kathy Mauk as administrator of the estate of Lindsey Poteet a/k/a Lindsey Richardson, deceased and on behalf of the wrongful death beneficiary of Lindsey Poteet a/k/a Lindsey Richardson, Arwen Richardson, vs. CRC Health Tennessee, Inc. dba New Life Lodge and CRC Health Group, Inc. dba New Life Lodge. The suit alleged negligence and medical malpractice resulting in wrongful death and sought a total $32.0 million in compensatory and punitive damages. This suit was settled at mediation in December 2013 within the amounts previously reserved.

In a complaint filed in December 2012, a suit against our New Life Lodge facility was brought by Charity Comage as administrator of the estate of and on behalf of Savon Kinney, deceased vs CRC Health Tennessee, Inc. dba New Life Lodge and CRC Health Group, Inc. dba New Life Lodge, American Behavioral Consultants, LLC and Holly Liter, APN. This suit alleges negligence and medical malpractice resulting in the wrongful death and seeking a total $14.5 million in compensatory and punitive damages. American Behavioral Consultants, LLC served as an independent contractor for New Life Lodge and Ms. Holly Liter was an employee of American Behavioral Consultants, LLC. In a complaint filed in June 2013, a suit against our New Life Lodge was brought by Penny Bryant, mother of Patrick Bryant, deceased, vs. CRC Health Tennessee, Inc. and Jonathan Butler, M.D. This suit was originally filed in 2011 and then dismissed without prejudice in October 2012 and was re-filed in June 2013. This suit alleges negligence resulting in the wrongful death of Patrick Bryant and seeks a total of $13.0 million in compensatory and punitive damages. We intend to defend vigorously these lawsuits. In consultation with counsel and based on our preliminary investigation into the facts alleged, we believe these cases are without merit. Although the Company believes the amounts reserved are adequate based on currently available information, the estimation process involves a considerable amount of judgment by management and the ultimate amounts could vary materially.

In 2013, our New Life Lodge facility responded to a civil investigative demand from the Office of the Attorney General of the State of Tennessee inquiring about possible false claims for payment related to services provided to TennCare recipients for the period 2006 to 2011. The United States Department of Justice participated in this investigation and has also requested information from New Life Lodge. While the Company disputes the validity of the allegations in this suit, in order to avoid the distraction of a protracted legal process, the Company agreed to settle this lawsuit joined by the State of Tennessee and the US Department of Justice related to the services provided in the past to TennCare patients who sought care at New Life Lodge between 2006 and 2011 for a total of $9.3 million all of which was expensed in the nine months ended September 30, 2013. This settlement amount was paid in April 2014.

In 2012, the U.S. Department of Justice / Drug Enforcement Administration, (“DEA”) issued subpoenas to six (6) clinics owned by the Company, requiring the Company to provide certain books, records and papers related to the practice by such clinics to accept and destroy surrendered medications. In May 2014, the Company received a Notice of Hearing for such clinics requesting an informal hearing at the offices of the DEA. The DEA / US Department of Justice allege that the Company failed to keep proper records regarding the return and destruction of surrendered medications and failed to properly execute certain record keeping forms. The Company participated in the hearing and as a result is currently negotiating a memorandum of agreement to resolve the

14

administrative part of these alleged recordkeeping violations. The US Department of Justice has also made a civil penalty demand of $7 million in regard to the same alleged record keeping violations. We intend to defend vigorously these allegations. In consultation with counsel and based on our preliminary investigation into the facts alleged, the Company maintains that it has certain defenses to these allegations. Although the Company believes the amounts reserved are adequate based on currently available information, the estimation process involves a considerable amount of judgment by management and the ultimate amounts could vary materially.

We are involved in other litigation and regulatory investigations arising in the ordinary course of business. After consultation with legal counsel, management estimates that these matters will be resolved without material adverse effect on our future financial position or results from operations and cash flows, except as discussed above. As of September 30, 2014 and December 31, 2013, accruals for legal matters totaled $1.7 million and $12.4 million respectively, and were included in ‘accrued expenses’ in the Condensed Consolidated Balance Sheets.

NOTE 8. RELATED PARTY TRANSACTIONS

The Company maintains a management agreement with an affiliate of Bain Capital Partners, LLC to provide management services. The management agreement provides that an affiliate of Bain Capital Partners, LLC may receive fees in connection with certain financing and acquisition transactions.

Under the agreement, the Company incurred management fees of $1.8 million during both nine month periods ended September 30, 2014 and 2013. The management fee is included in facilities and other operating costs in the Company’s Consolidated Statements of Operations. Also under this agreement, the Company paid $8.3 million in connection with certain debt financing transactions during the nine months ended September 30, 2014. These fees were recorded as capitalized financing costs.

NOTE 9. STOCK-BASED COMPENSATION

For the nine months ended September 30, 2014 and 2013, the Company recognized stock-based compensation expense (income) of $1.9 million and ($0.6) million respectively, within salaries and benefits in the consolidated statements of operations.

During the nine months ended September 30, 2014, the results of operations include the reversal of previously recorded stock-based compensation of $0.6 million related to the forfeiture of certain performance based stock option awards. During the nine months ended September 30, 2013, the results of operations include the reversal of previously recorded stock-based compensation of $2.6 million based upon the determination that it was not probable of achieving the performance criteria and requisite service period for certain performance based stock option awards.

NOTE 10. INCOME TAXES

The Company calculates its income tax expense for interim periods by applying the full year’s estimated effective tax rate in its financial statements for interim periods (in thousands).

	Nine Months Ended September 30,
	2014			2013
Income (loss) from continuing operations before income taxes	$	(5,690	)	$	449
Income tax expense (benefit) from continuing operations		254			1,261

The Company has a full valuation allowance against its deferred tax assets for federal income tax purposes and the tax expense for the nine months ended September 30, 2014 and 2013 represents state income taxes.

15

NOTE 11. RESTRUCTURING

In the nine months ended September 30, 2014, the Company paid employee severance of $0.6 million and recorded a lease termination liability in the amount of $0.3 million. As of September 30, 2014, the Company’s restructuring reserve of $17.2 million (of which $13.6 million is included in long-term liabilities of discontinued operations and facilities held-for-sale) consists primarily of future rental payments net of estimated sublease income. These cash payments are expected to continue through 2020 and are summarized in the following table (in thousands):

Total restructuring reserve at December 31, 2013	$	19,212
Additional restructuring reserve		260
Expenses		987
Cash payments		(3,290	)
Total restructuring reserve at September 30, 2014	$	17,169

NOTE 12. DISCONTINUED OPERATIONS

During the nine months ended September 30, 2014, the Company classified two facilities as discontinued operations. One facility was closed in March 2014 and the Company recognized a loss of $0.6 million related to the closure. The other facility was sold in August 2014 and the Company recognized a loss of $2.2 million related to the sale.

The Company completed the sale of the Wellspring Camps and four Youth facilities in 2014. These operations had been classified as held for sale at December 31, 2013. The Company recorded a $0.9 million loss in the nine months ended September 30, 2014 related to these sales.

The results of operations for those facilities classified as discontinued operations are summarized below (in thousands).

	Nine Months Ended September 30,
	2014			2013
Net client service revenues	$	7,489		$	39,758
Operating expenses		11,563			69,389
Interest income		(2	)		(6	)
Loss before income taxes		(4,072	)		(29,625	)
(Gain) loss on disposal of discontinued operations		3,139			(522	)
Income tax benefit		(609	)		(64	)
Loss from discontinued operations	$	(6,602	)	$	(29,039	)

NOTE 13. SUBSEQUENT EVENTS

The Company performed an evaluation of subsequent events from the balance sheet date of September 30, 2014 through January 27, 2015, the date the condensed consolidated financial statements were available to be issued and concluded that there are no additional events requiring recording or disclosure in the consolidated financial statements, except as described below.

On October 29, 2014, the Company entered into a definitive agreement to be acquired by Acadia Healthcare Company, Inc. (“Acadia”). Total consideration for the acquisition will be approximately $1.2 billion, consisting of up to approximately 6.3 million shares of Acadia’s common stock and the assumption of the Company’s debt. The transaction is expected to close in the first quarter of 2015, and is subject to regulatory review and other normal closing conditions.

16

EX-99.4

Exhibit 99.4

Partnerships in Care Investments 1 Limited

Unaudited interim condensed combined financial statements for the

six months ended 30 June 2014

Partnerships in Care Investments 1 Limited

Contents

	Page
Interim condensed combined profit and loss account		3
Interim condensed combined statement of total recognised gains and losses		4
Interim condensed combined balance sheet		5
Interim condensed combined cash flow statement		6
Reconciliation of net cash flow to movement in net debt		6
Notes to the interim condensed combined financial statements		7

2

Partnerships in Care Investments 1 Limited

Interim condensed combined profit and loss account

	Note	6 months to 30 June 2014 £000 (Unaudited)			6 months to 30 June 2013 £000 (Unaudited)			12 months to 31 December 2013 £000 (Audited)
Turnover	4		85,283			84,910			170,703
Cost of sales			(57,426	)		(54,789	)		(109,625	)
Gross profit			27,857			30,121			61,078
Administrative expenses			(14,641	)		(14,670	)		(30,041	)
Operating profit			13,216			15,451			31,037
Interest receivable and similar income			19			18			35
Interest payable and similar charges	5		(31,963	)		(30,464	)		(61,784	)
Other finance expenses			(35	)		(16	)		(33	)
Loss on ordinary activities before taxation			(18,763	)		(15,011	)		(30,745	)
Tax on loss on ordinary activities	6		1,063			943			1,715
Loss for the period			(17,700	)		(14,068	)		(29,030	)

All amounts relate to continuing operations.

There were no recognised gains and losses for the six months ended 30 June 2014 or the six months ended 30 June 2013 other than those included in the Profit and loss account.

There are no material differences between the loss on ordinary activities before taxation and the loss for the period stated above and their historical cost equivalents.

The accompanying notes form an integral part of the interim condensed combined financial statements.

3

Partnerships in Care Investments 1 Limited

Interim condensed combined statement of total recognised gains and losses

	6 months to 30 June 2014 £000 (Unaudited)			6 months to 30 June 2013 £000 (Unaudited)			12 months to 31 December 2013 £000 (Audited)
Loss for the financial period		(17,700	)		(14,068	)		(29,030	)
Actuarial loss related to pension scheme		—			—			(2,939	)
Deferred tax attributable to actuarial loss		—			—			683
Total recognised gains and losses relating to the period		(17,700	)		(14,068	)		(31,286	)

The accompanying notes form an integral part of the combined financial statements.

4

Partnerships in Care Investments 1 Limited

Interim condensed combined balance sheet

	Note	At 30 June 2014 £000 (Unaudited)			At 31 December 2013 £000 (Audited)
Fixed assets
Tangible assets			453,113			454,844
Current assets
Stocks			592			628
Debtors			7,636			7,045
Cash at bank and in hand			11,862			15,817
			20,090			23,490
Creditors: amounts falling due within one year			(12,737	)		(13,306	)
Net current assets			7,353			10,184
Total assets less current liabilities			460,466			465,028
Creditors: amounts falling due after more than one year	7		(800,286	)		(786,725	)
Provisions for liabilities
Deferred tax			(1,495	)		(2,559	)
Net liabilities excluding pension scheme liability			(341,315	)		(324,256	)
Pension liability			(3,676	)		(3,913	)
Net liabilities			(344,991	)		(328,169	)
Capital and reserves
Net Investment of Parent			(344,991	)		(328,169	)
Shareholders’ deficit	8		(344,991	)		(328,169	)

The accompanying notes form an integral part of the interim condensed combined financial statements.

5

Partnerships in Care Investments 1 Limited

Interim condensed combined cash flow statement

	Note	6 months to 30 June 2014 £000 (Unaudited)			6 months to 30 June 2013 £000 (Unaudited)			12 months to 31 December 2013 £000 (Audited)
Net cash flow from operating activities	9		18,552			17,721			41,199
Returns on investments and servicing of finance	10		(4,865	)		(5,260	)		(10,309	)
Taxation			312			208			254
Capital expenditure and financial investment	10		(4,304	)		(4,518	)		(9,163	)
Cash inflow before financing			9,695			8,151			21,981
Financing	10		(13,650	)		(14,733	)		(24,288	)
(Decrease)/Increase in cash in the period			(3,955	)		(6,582	)		(2,307	)

Reconciliation of net cash flow to movement in net debt

	6 months to 30 June 2014 £000 (Unaudited)			6 months to 30 June 2013 £000 (Unaudited)
Decrease in cash in the period		(3,955	)		(6,582	)
Decrease in borrowings		13,650			14,733
Change in net debt resulting from cash flows		9,695			8,151
Other non-cash changes		(27,211	)		(25,365	)
Movement in net debt in the period		(17,516	)		(17,214	)
Net debt at 1 January		(771,828	)		(742,120	)
Net debt at 30 June		(789,344	)		(759,334	)

The accompanying notes form an integral part of the interim condensed combined financial statements.

6

Partnerships in Care Investments 1 Limited

Notes to the interim condensed combined financial statements

1. Nature of business

Partnerships in Care Investments 1 Limited (the “Company”) is a subsidiary of Partnerships in Care Group Limited (the “Parent” or “PiC Group Limited”) and of Partnerships in Care Holdings Limited (together, “the parent companies”). The Parent and its subsidiary undertakings (“the Group”) have historically prepared consolidated financial statements of the Group which has been managed as a business by a single management team. The accompanying unaudited interim condensed combined financial statements reflect the assets, liabilities, revenues and expenses directly attributed to Partnerships in Care Investments 1 Limited and its subsidiary undertakings, as well as certain liabilities and expenses of the Parent as described below (together referred to as the “Business”). The unaudited interim condensed combined financial statements of the Business for the six months ended 30 June 2014 and 30 June 2013 (“the interim condensed combined financial statements”) are prepared in accordance with the ASB statement on half-yearly financial reports and on the basis set out below.

The Business is one of the largest UK independent providers of secure and step down services to patients in facilities operated by the Business and which include medium and low security, and inpatient rehabilitation for patients with mental health, personality disorder, learning disability and similar conditions.

On 2 June 2014, the Business entered into a contract for the sale of Partnerships in Care Investments 1 Limited to Acadia Healthcare Company, Inc (“Acadia”) for consideration of £395m. The sale completed on 1 July 2014.

2. Accounting policies

2.1 Basis of preparation

The unaudited interim condensed combined financial statements reflect all adjustments which are, in the opinion of management, necessary to a fair statement of the results of the interim periods presented. Such adjustments are of a normal recurring nature. These unaudited interim condensed combined financial statements should be read in conjunction with our audited combined financial statements and notes thereto for the year ended 31 December 2013. These interim condensed combined financial statements have been prepared by the Directors of the Company on the basis set out below. The Directors believe that the basis of preparation applied is appropriate for the intended use of these financial statements, which is to provide historical financial information to Acadia to assist Acadia in satisfying its reporting responsibilities under Regulation S-X, Rule 3-05, Financial statements of businesses acquired or to be acquired.

These interim condensed combined financial statements are not the statutory financial statements of the Company prepared in accordance with section 394 of the Companies Act 2006. Accordingly, these financial statements do not present information on Partnerships in Care Investments 1 Limited as a separate legal entity.

These interim condensed combined financial statements reflect the historical financial position, results of operations, parent company equity and cash flows of the Business for the periods presented. The historical financial statements reflect the amounts that have been “carved-out” from the Parent’s consolidated financial statements prepared in accordance with applicable accounting standards in the United Kingdom (“UK GAAP”) and reflect assumptions and allocations made by the Parent to depict the Business on a stand-alone basis. As a result, the interim condensed combined financial statements included herein may not necessarily be indicative of the Business’s financial position, results of operations, or cash flows had the Business operated as a stand-alone entity during the periods presented.

The interim condensed combined financial statements were prepared using the Parent’s historical records of the assets and liabilities of the Business, and the historical interim condensed combined financial statements

7

Partnerships in Care Investments 1 Limited

Notes to the interim condensed combined financial statements

include all assets, liabilities, revenues and expenses directly attributable to the Business. The Business has been partially financed by borrowings from the parent companies. The parent companies have in turn been financed by the ultimate controlling party through the issue of unsecured subordinated loan notes and PIK notes, and in substance those loans have been used to finance the operations of the group headed by Partnerships in Care Investments 1 Limited. Accordingly, the Directors consider it appropriate for the purpose of these interim condensed combined financial statements to apply the push down accounting principles contained in Staff Accounting Bulletin Topic 5J that discusses push down of debt. All related costs of servicing the pushed down debt have been included in the Business.

The amounts that have been legally incurred by the parent companies but which have been pushed down to the Business are set out in Note 13.

All such costs and expenses have been deemed to have been paid by the Business to the Parent in the period in which the costs were incurred. The Net Investment of Parent in the Business as shown in the interim condensed combined balance sheet includes amounts due to / from PiC Group Limited as well as certain intercompany receivables / payables with Partnerships in Care Holdings Limited.

2.2 Going concern

On 2 June 2014, the Business exchanged contracts for the sale of Partnerships in Care Investments 1 Limited to Acadia Healthcare Company, Inc (“Acadia”) for consideration of £395m. The sale was completed on 1 July 2014.

As described in Note 2.1 above, the application of “push down accounting” principles has resulted in the inclusion in these financial statements of certain debenture loan notes including PIK notes and other loans which are not liabilities of the Business. These liabilities were not acquired by Acadia and were never required to be repaid or extinguished by the Business headed by Partnerships in Care Investments 1 Limited. Details of those finance facilities are set out in Note 7 to these financial statements.

On completion of the sale, the Business repaid the majority of its senior bank debt extant at that time from the proceeds of the transaction. Furthermore, the Business issued “A” Ordinary Shares in PiC Property 1 Limited to its bankers in consideration for the release of any remaining bank debt (as described in Note 15). These “A” Ordinary Shares were sold to Acadia for a nominal amount. Together these transactions at the completion date resulted in the extinguishment of all the Business’s bank debt and any related accrued interest and capitalised finance costs.

Acadia has provided written confirmation to the Directors of Partnerships in Care Investments 1 Limited that it will continue to provide funds to the Business to enable it to repay its debts as and when they fall due, for a period of at least one year from the date of approval of these interim condensed combined financial statements. Accordingly, the Directors consider it appropriate to adopt the going concern basis in preparing these interim condensed combined financial statements.

2.3 Other accounting policies

Other than as set out below the accounting policies are consistent with those of the previous financial year.

The Group only measures actuarial gains and losses relating to its defined benefit pension scheme on an annual basis. Accordingly, these interim financial statements are prepared on the basis that any actuarial gains or losses arising in the periods presented would have been immaterial.

3. Seasonality

There is no significant seasonality in the business.

8

Partnerships in Care Investments 1 Limited

Notes to the interim condensed combined financial statements

4. Turnover

The directors are of the opinion that the businesses of the Group are substantially similar in that they all relate to the provision of healthcare services; therefore there is only one class of business.

All turnover arose within the United Kingdom.

5. Interest payable and similar charges

	6 months to 30 June 2014 £000 (Unaudited)		6 months to 30 June 2013 £000 (Unaudited)		12 months to 31 December 2013 £000 (Audited)
On bank loans and overdrafts		14,596		14,692		29,254
On other loans		17,367		15,770		32,528
Other interest payable		—		2		2
		31,963		30,464		61,784

6. Taxation

Income tax expense is recognised based on management’s estimate of the weighted average annual income tax rate expected for the full financial year. The estimated average annual tax rate used for the year to 31 December 2014 is 20% (31 June 2013: 23.25%).

7. Borrowings

	At 30 June 2014 £000 (Unaudited)			At 31 December 2013 £000 (Audited)
Amounts falling due within one year:
Other loans		920			920
Amounts falling due after one year:
Unsecured loan notes including PIK notes		371,357			354,075
Bank loans		444,812			455,104
Capitalised amounts		(15,883	)		(22,454	)
		800,286			786,725

The Business has been partially financed by borrowings from its parent companies Partnerships in Care Holdings Limited and Partnerships in Care Group Limited (“the parent companies”). The parent companies have in turn been financed by the ultimate controlling party through the issue of unsecured subordinated loan notes and PIK notes (including ‘other loans’ and ‘debenture loans’ above), and in substance those loans have been used to finance the operations of the group headed by Partnerships in Care Investments 1 Limited. Accordingly, the Directors consider it appropriate for the purpose of these interim condensed combined financial statements to apply the push down accounting principles contained in Staff Accounting Bulletin Topic 5 J that discusses push down of debt.

Details of the Group’s borrowings are set out below:

A bank loan of £23,896,014 (2013 - £25,844,806) is secured by way of a fixed legal charge over subsidiary companies’ assets, with an interest rate varying with LIBOR maturing in July 2015.

9

Partnerships in Care Investments 1 Limited

Notes to the interim condensed combined financial statements

A bank loan of £420,916,076 (2013 - £429,259,353) is secured by way of a fixed legal charge over subsidiary companies’ assets, with an interest rate varying with LIBOR maturing in July 2015.

The Group had taken out an interest rate swap to hedge the interest rate on the Group’s bank borrowings. As part of the amended financing arrangements agreed on 28 September 2011, the existing interest rate swap was capitalised at £47,226,894 and is being amortised to the profit and loss account over the remaining life of the bank loan until July 2015.

A loan amounting to £920,000 (2013 - £920,000) at the period end from the majority shareholder which is interest free and repayable on demand.

Unsecured subordinated loan notes amounting to £369,933,686 (2013 - £352,716,882) at the period end due 2020 on which unsecured subordinated PIK notes due 2020 have been issued up to March 2011 to satisfy interest at 10% per annum. From April 2011 these loans have been accruing compound interest at 10% per annum.

Unsecured fixed rate loan notes amounting to £1,423,329 (2013 - £1,358,483) due 2020 with compound interest at 10% per annum.

8. Reconciliation of movement in shareholders’ deficit

Group	6 months to 30 June 2014 £000 (Unaudited)			6 months to 30 June 2013 £000 (Unaudited)			12 months to 31 December 2013 £000 (Audited)
Opening shareholders’ deficit		(328,169	)		(298,384	)		(298,384	)
Loss for the period		(17,700	)		(14,068	)		(29,030	)
Share based payments		878			751			1,501
Actuarial loss from pension scheme, net of tax		—			—			(2,256	)
Closing shareholders’ deficit		(344,991	)		(311,701	)		(328,169	)

9. Net cash flow from operating activities

	6 months to 30 June 2014 £000 (Unaudited)			6 months to 30 June 2013 £000 (Unaudited)			12 months to 31 December 2013 £000 (Audited)
Operating profit		13,216			15,451			31,037
Share based payments		878			751			1,501
Depreciation of tangible fixed assets		5,991			5,617			11,458
Loss/(Profit) on disposal of tangible fixed assets		47			—			(26	)
Decrease/(Increase) in stocks		36			(70	)		(6	)
(Increase)/decrease in debtors		(901	)		(2,577	)		(340	)
(Decrease) in creditors		(456	)		(722	)		(2,066	)
(Decrease) in net pension deficit		(259	)		(729	)		(359	)
Net cash inflow from operating activities		18,552			17,721			41,199

10

Partnerships in Care Investments 1 Limited

Notes to the interim condensed combined financial statements

10. Analysis of cash flows for headings netted in cash flow statement

	6 months to 30 June 2014 £000 (Unaudited)			6 months to 30 June 2013 £000 (Unaudited)			12 months to 31 December 2013 £000 (Audited)
Returns on investments and servicing of finance
Interest received		19			18			35
Interest paid		(4,884	)		(5,278	)		(10,344	)
Net cash outflow from returns on investments and servicing of finance		(4,865	)		(5,260	)		(10,309	)

	6 months to 30 June 2014 £000 (Unaudited)			6 months to 30 June 2013 £000 (Unaudited)			12 months to 31 December 2013 £000 (Audited)
Capital expenditure and financial investment
Purchase of tangible fixed assets		(4,317	)		(4,526	)		(9,239	)
Sale of tangible fixed assets		13			8			76
Net cash outflow from capital expenditure		(4,304	)		(4,518	)		(9,163	)

	6 months to 30 June 2014 £000 (Unaudited)			6 months to 30 June 2013 £000 (Unaudited)			12 months to 31 December 2013 £000 (Audited)
Financing
Repayment of loans		(13,650	)		(14,733	)		(24,288	)
Net cash outflow from financing		(13,650	)		(14,733	)		(24,288	)

11. Analysis of changes in net debt

	1 January 2014 £000 (Audited)			Cash flow £000 (Unaudited)			Other non-cash changes £000 (Unaudited)			30 June 2014 £000 (Unaudited)
Cash at bank and in hand		15,817			(3,955	)		—			11,862
Debt:
Debts due within one year		(920	)		13,650			(13,650	)		(920	)
Debts falling due after more than one year		(786,725	)		—			(13,561	)		(800,286	)
Net debt		(771,828	)		9,695			(27,211	)		(789,344	)

11

Partnerships in Care Investments 1 Limited

Notes to the interim condensed combined financial statements

	1 January 2013 £000 (Audited)			Cash flow £000 (Unaudited)			Other non-cash changes £000 (Unaudited)			30 June 2013 £000 (Unaudited)
Cash at bank and in hand		18,124			(6,582	)		—			11,542
Debt:
Debts due within one year		(920	)		14,733			(14,733	)		(920	)
Debts falling due after more than one year		(759,324	)		—			(10,632	)		(769,956	)
Net debt		(742,120	)		8,151			(25,365	)		(759,334	)

	1 January 2013 £000 (Audited)			Cash flow £000 (Audited)			Other non-cash changes £000 (Audited)			31 December 2013 £000 (Audited)
Cash at bank and in hand		18,124			(2,307	)		—			15,817
Debt:
Debts due within one year		(920	)		24,288			(24,288	)		(920	)
Debts falling due after more than one year		(759,324	)		—			(27,401	)		(786,725	)
Net debt		(742,120	)		21,981			(51,689	)		(771,828	)

12. Contingent liabilities

As at 30 June 2014, the Business had a contingent liability to Cinven Limited for an amount of up to £10 million dependent on the repayment of certain debt facilities of the Group. These contingency liabilities were removed as part of the Acadia transaction as described in Note 15, “Post balance sheet events”.

13. Related party transactions

Push down accounting

The Business has been partially financed by borrowings from its parent companies Partnerships in Care Holdings Limited and Partnerships in Care Group Limited (“the parent companies”). The parent companies have in turn been financed by the ultimate controlling party through the issue of unsecured subordinated loan notes and PIK notes, and in substance those loans have been used to finance the operations of the group headed by Partnerships in Care Investments 1 Limited. Accordingly, the Directors consider it appropriate for the purpose of these interim condensed combined financial statements to apply the push down accounting principles contained in Staff Accounting Bulletin Topic 5 J that discusses push down of debt:

	At 30 June 2014 £000 (Unaudited)		At 31 December 2013 £000 (Unaudited)
Other loans		920		920
Debenture loans (non current)		371,357		354,075
		372,277		354,995

12

Partnerships in Care Investments 1 Limited

Notes to the interim condensed combined financial statements

The interim condensed combined financial statements include interest allocations relating to the above debt:

	6 months to 30 June 2014 £000 (Unaudited)		6 months to 30 June 2013 £000 (Unaudited)		12 months to 31 December 2013 £000 (Audited)
Interest payable and similar charges		17,367		15,770		32,528
		17,367		15,770		32,528

Transactions with directors

Kevin Beeston, a director, holds 22,000 A Ordinary shares (2013 - 22,000 A Ordinary shares) in the Company.

Transactions with Cinven

Funds under the management of Cinven Limited have invested in two subordinated loan notes totalling £369,933,686 (2013 - £352,716,682). During the period interest amounting to £17,217,004 (2013 - £32,065,153) was rolled into these loan notes.

The same Cinven funds have invested in two other loan notes totalling £718,678 (2013 - £646,757). During the period interest amounting to £31,096 (2013 - £28,269) was rolled into these loan notes.

Funds under the management of Cinven Limited have invested in an unsecured fixed rate loan of £920,000 (2013 - £920,000).

Cinven Limited charged a monitoring fee during the period amounting to £150,000 (2013 - £150,000).

14. Controlling party

As at 30 June 2014, the immediate parent company was Partnerships in Care Holdings Limited and the ultimate parent entity was PIC Investments Limited Partnership Incorporated, a limited partnership established and existing under the laws of Guernsey.

The directors are of the opinion that Cinven Limited is the controlling party at 30 June 2014. Funds managed by Cinven Limited have a 100% interest in the ultimate parent company. Cinven Limited is incorporated in England and Wales with registered offices at Warwick Court, Paternoster Square, London EC4M 7AG.

After the sale of the Business completed on 1 July 2014, the ultimate parent company is Acadia Healthcare Company, Inc. See Note 15, “Post balance sheet events”.

15. Post balance sheet events

On 2 June 2014, Partnerships in Care Holdings Limited exchanged contracts for the Company to be sold to Acadia Healthcare Company, Inc. for consideration of £395m. The sale was completed on 1 July 2014 and the bank debt was either repaid or released in full on completion.

As described in Note 2.1 above, the application of “push down accounting” principles has resulted in the inclusion in these interim financial statements of certain debenture loans and PIK notes which are not liabilities of the Business. These liabilities were not acquired by Acadia and will never require repayment or extinguishment by the Business headed by Partnerships in Care Investments 1 Limited. Details of those finance facilities are set out in Note 7 to these interim condensed combined financial statements.

13

Partnerships in Care Investments 1 Limited

Notes to the interim condensed combined financial statements

16. Reconciliation from UK GAAP to US GAAP

These interim condensed combined financial statements have been prepared in accordance with the basis of preparation as set out in Note 2.1, and have been “carved out” of consolidated financial statements of the Parent which were prepared in accordance with applicable accounting standards in the United Kingdom (“UK GAAP”) which differs in certain significant respects from accounting principles generally accepted in the United States of America (“US GAAP”). The effects of the application of US GAAP to the loss for the period after taxation, as determined under UK GAAP for the six months ended 30 June 2014, 30 June 2013 and 31 December 2013, are set out in the tables below:

a) Loss for the periods ended 30 June 2014, 30 June 2013 and 31 December 2013

	For 30 June 2014 £000 (Unaudited)			For 30 June 2013 £000 (Unaudited)			For 31 December 2013 £000 (Audited)
Loss for the periods under UK GAAP		(17,700	)		(14,068	)		(29,030	)
(i)     Reversal of share based payment expense		878			751			1,501
(ii)    Impact of reversal of PPE impairment in prior years		(1,039	)		(1,039	)		(2,077	)
(iii)  Interest rate hedging		6,160			6,160			12,320
(iv)   Deferred taxes		(57	)		4,030			6,883
(v)    Tax impact of above differences		(1,024	)		(1,024	)		(387	)
Loss for the periods under US GAAP		(12,782	)		(5,190	)		(10,790	)

b) Balance sheet as at 30 June 2014 and 31 December 2013

	30 June 2014 £000 (Unaudited)			31 December 2013 £000 (Audited)
Shareholders’ deficit as at 30 June 2014 and 31 December 2013 under UK GAAP		(344,991	)		(328,169	)
(ii)    Reversal of PPE impairment		84,108			85,146
(iii)  Interest rate hedging		(13,347	)		(19,507	)
(iv)   Deferred taxes		(30,081	)		(30,024	)
(v)    Tax impact of above differences		(14,152	)		(13,128	)
Shareholders’ deficit as at 30 June 2014 and 31 December 2013 under US GAAP		(318,463	)		(305,682	)

(i) Under UK GAAP, a share based payment expense of £878,000 (2013: £751,000) was recognised in the six months ended 30 June 2014. The vesting of the shares awarded in connection with the Management Incentive Plan is restricted until a change of control event. Under US GAAP, such a performance condition is highly uncertain and, therefore, is not probable; as such, no expense is recognised.

(ii) Under UK GAAP, an impairment of £89,300,000 was recognised in the year ended 31 December 2011. Under US GAAP, this impairment is not recognised as, in conducting the first step of the two-step impairment test under US GAAP, the undiscounted cash flows of fixed assets exceeded the carrying value. The adjustments above of £1,039,000 per half year are the impact on depreciation in subsequent years arising as a result of reversing the impairment under US GAAP.

(iii) Under UK GAAP, the interest swap taken out to hedge the interest rates on the Business’s borrowings until September 2011 was off-balance sheet. Upon refinancing, the fair value of the instrument of £47,227,000

14

Partnerships in Care Investments 1 Limited

Notes to the interim condensed combined financial statements

was capitalised and amortised over the remaining life of the debt facilities. Under US GAAP, this derivative financial instrument would have been carried at its fair value at each balance sheet date, with gains and losses being recorded to the income statement (since no formal hedge documentation was produced). Upon cessation of the agreement in 2011, any gain / loss would have been recognised in the income statement immediately. Therefore, the amortisation of the capitalised amount in each of the six month periods ended 30 June 2014 of £6,160,000(2013 -£6,160,000) has been reversed under US GAAP.

(iv) Under UK GAAP, provision is made for deferred tax assets and liabilities arising from all timing differences between the recognition of gains and losses in the financial statements and recognition in the tax computation. US GAAP uses the “asset and liability method” of accounting for income taxes whereby deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities using tax rates that are expected to apply in the years the temporary differences are expected to reverse. The principal differences relate to deferred taxes on property, plant and equipment.

(v) This adjustment reflects the tax impact of the above GAAP differences, including effective tax rate changes in the UK.

15

Partnerships in Care Investments 1 Limited

Notes to the unaudited interim condensed combined financial statements

c) Cash flow statement for the six months ended 30 June 2014, the six months ended 30 June 2013 and the year ended 31 December 2013

The interim condensed combined cash flow statements have been prepared under UK GAAP and present substantially the same information as required under US GAAP. There are certain differences with regard to classification of items within the cash flow statements. Under UK GAAP, cash flows are prepared separately for operating activities, returns on investments and servicing of finance, taxation, capital expenditures and financial investment, acquisitions and disposals, and financing. Under US GAAP, cash flows are classified under three major categories: operating activities, investing activities and financing activities. Under UK GAAP, cash is defined as cash in hand and deposits repayable on demand, less overdrafts repayable on demand. Under US GAAP, cash and cash equivalents are defined as cash and investments with original maturities of three months or less. The following table presents cash flows as classified under US GAAP.

	For the six months ended 30 June 2014 £000 (Unaudited)			For the six months ended 30 June 2013 £000 (Unaudited)			For the year ended 31 December 2013 £000 (Audited)
Operating activities:
Operating profit		13,055			15,163			30,461
Depreciation of tangible fixed assets		7,030			6,656			13,535
(Gain)/loss on disposal of tangible fixed assets		47			—			(26	)
Decrease/(Increase) in stocks		36			(70	)		(6	)
Increase in debtors		(901	)		(2,577	)		(340	)
Decrease in creditors		(456	)		(722	)		(2,066	)
Difference between pension payments and charge to operating profit		(259	)		(729	)		(359	)
Interest received		19			18			35
Interest paid		(4,884	)		(5,278	)		(10,344	)
Taxes paid		312			208			254
Net cash flow from operating activities		13,999			12,669			31,144
Investing activities:
Capital expenditure and financial investment		(4,304	)		(4,518	)		(9,163	)
Net cash used in investing activities		(4,304	)		(4,518	)		(9,163	)
Financing activities:
Financing		(13,650	)		(14,733	)		(24,288	)
Net cash used in financing activities		(13,650	)		(14,733	)		(24,288	)
Net (decrease) increase in cash and cash equivalents		(3,955	)		(6,582	)		(2,307	)
Cash and cash equivalents, beginning of period		15,817			18,124			18,124
Cash and cash equivalents, end of period		11,862			11,542			15,817

16